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Matthew Patrick Hanley, Ph.D.
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Colorectal cancer (CRC) is the 3rd most common form of cancer in the United States, and the 2nd
most common cause of cancer-related death. CRC incidence has declined over the past several decades,
however, there is a continued need for improved methods of CRC detection and prevention. Methyl group
homeostasis, which is dysregulated in CRC and impacts several fundamental biological processes,
represents a promising target for novel CRC detection and prevention strategies. DNA methylation is
influenced by methyl group homeostasis and is known to be frequently dysregulated in CRC. However,
less is known about the extent of aberrant methylation in early colonic neoplasia. We utilized reduced
representation bisulfite sequencing (RRBS) to identify cancer-associated methylation changes in 10 KRASmutant human aberrant crypt foci (ACF), the earliest precursor to CRC, and 10 primary CRCs. Using this
approach, extensive methylation changes were identified in both ACF and CRCs, including
hypermethylation of homeobox genes and Polycomb repressive complex 2 (PRC2) gene targets.
Furthermore, we show that intergenic binding sites for the transcription factor AP-1 undergo significant
hypomethylation. Importantly, 75% of the methylation changes identified in ACF were also present in CRC
samples. These data identify epigenomic features of early colonic neoplasia that may provide new targets
for CRC detection and prevention.
Folate one-carbon metabolism (FOCM), which regulates methyl group homeostasis, has been
proposed as a target for CRC prevention strategies. The present work shows that dietary restriction of the
methyl donors folate, choline, methionine and vitamin B12 provides long-lasting tumor protection to the

Matthew Patrick Hanley – University of Connecticut, 2017

intestine. Tumor protection was associated with persistent remodeling of intestinal morphology,
inhibition of crypt fission, reduced crypt cell mitosis, and increased apoptosis in both normal crypts and
tumors. MDD also reduced numbers of crypt cells expressing Dclk1, which have tumor-initiating potential.
In a follow-up study, we used untargeted metabolomic profiling to identify MDD-associated changes to
several metabolic pathways, including the methionine cycle, the transsulfuration pathway, secondary bile
acid synthesis, and fatty acid β-oxidation (FAO). Together, these results indicate that temporary MDD can
provide long-lasting tumor protection and identify several pathways that may serve as novel targets for
CRC chemoprevention.
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Chapter 1: Introduction
1.1 Colorectal Cancer
Together, cancers of the colon and rectum, collectively referred to as “colorectal cancer” (CRC), are
the third most commonly diagnosed cancer in the United States (1). In 2016, there were ~130,000 new
cases and ~50,000 deaths due to CRC in the US, making this disease the second most common cause of
cancer-related death in the country. Incidence and mortality associated with CRC have declined over the
past several decades (2), primarily due to improvements in the development and implementation of
effective screening modalities. However, the risk of CRC increases dramatically with age (3) and it is
anticipated that CRC incidence will increase as the average age of the US population increases (4). Survival
rates for CRC remain low; the 5-year survival rate for CRC is 65% overall, and only 11% for cancers detected
in Stage IV (1). Thus, there is a continued need for improvements in the early detection and prevention of
CRC.
CRC develops slowly, arising via a series of precursor lesions in a step-wise progression known as the
adenoma-carcinoma sequence. Development of sporadic CRC begins with the acquisition of an “initiating”
mutation within a single colonic epithelial cell. The progression of a transformed epithelial cell to
carcinoma is driven by the acquisition of molecular aberrations that alter protein structure and function.
These molecular changes result in several phenotypic hallmarks, including uncontrolled proliferation,
resistance to cell death, and the induction of new vascular growth. Pathologically, this progression is
characterized by the growth of small neoplastic foci into larger adenomatous polyps, a subset of which
are able to develop into CRC. In cases of sporadic CRC, the mutation that initiates this process is acquired
spontaneously as the result of exposure to a mutagen or an error in cellular replication. However, in
certain hereditary CRC syndromes, such as Familial Adenomatous Polyposis (FAP), this initiating mutation
is passed from generation to generation, greatly increasing an affected individual’s risk of CRC. For many
reasons, current pharmacological and surgical therapies fail to eliminate advanced tumors (5). An
1

alternative strategy, which has led to significant reductions in CRC mortality, is to prevent the
development of CRC altogether by arresting or reversing the progression of precursor lesions.

1.2 Genetics and Molecular Biology of Colorectal Cancer
1.2.1

Genetic Mutations
The development of CRC is characterized by the accumulation of mutations within tumor

suppressors and proto-oncogenes. A tumor suppressor gene is a gene that protects a cell from
carcinogenesis by preventing uncontrolled cellular growth. Tumor suppressor genes frequently code for
proteins involved in the negative regulation of proliferation and mitosis, the DNA damage response, and
the initiation and execution of programmed cell death (“apoptosis”). Inactivation or loss of a tumor
suppressor gene enables carcinogenesis by eliminating these important protective mechanisms. In
contrast, oncogenes are created by the activation of “proto-oncogenes”, normal genes which gain the
ability to cause cancer via mutation or overexpression. Proto-oncogenes very often code for proteins that
are involved in the positive regulation of cell growth and differentiation, and their activation frequently
leads to abnormal increases in these processes. Proto-oncogenes are frequently involved in intracellular
signaling pathways, especially those regulating mitogenesis. Following mutation, oncogenes promote
abnormal activation of mitogenic signaling pathways, increase cellular proliferation, and actively drive
tumor growth. Cancers typically harbor multiple mutations, and it is generally accepted that changes to
tumor suppressors and oncogenes cooperate to promote oncogenesis.
While a variety of genes can be mutated in CRC, a fairly limited set of genes are mutated with high
enough frequency to be considered classical “drivers” of colonic oncogenesis. According to the adenomacarcinoma sequence originally proposed by Vogelstein (6), inactivating mutations in the tumor suppressor
gene Adenomatous polyposis coli (APC) are the most common initiating event in colorectal carcinogenesis.
This proposal is supported by the observation that APC is mutated in up to 80% of CRCs (7). Furthermore,
2

the hereditary cancer syndrome FAP, which carries a nearly 100% lifetime risk of CRC, is caused by a
heritable APC mutation (8). APC’s primary function is to regulate activation of the mitogenic Wnt-signaling
pathway, which is normally involved in the development and regeneration of the intestinal epithelium (9).
When the Wnt pathway is inactive, APC forms a “destruction complex” with the proteins Axin, casein
kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK3β) that binds the protein β-catenin and targets
it for proteasomal degradation (9). When the Wnt pathway is activated, this destruction complex
dissociates and β-catenin is able to accumulate within the cytoplasm. At a critical concentration, β-catenin
is translocated to the nucleus, where it acts as a coactivator for the TCF/LEF family of transcription factors
and upregulates the expression of genes that promote cellular proliferation and migration (9). Loss or
inactivation of APC prevents assembly of the destruction complex, leading to constitutive activation of the
Wnt signaling pathway and uncontrolled cellular proliferation. In CRC, mutations to APC are typically point
or frame-shift mutations that lead to the production of a non-functional protein. For sporadic CRC, the
majority of these mutations (95%) are located within the “mutational cluster region” (MCR) (10), which is
located in exon 15 and spans from codon 1286 to 1580. In hereditary CRC, only 23% of APC mutations fall
within the MCR.
Another tumor suppressor gene that is commonly mutated in CRC is TP53, which codes for tumor
protein p53 (p53), a critical regulator of DNA repair, cell cycle progression, and apoptosis that has been
described as the “guardian of the genome” (11). TP53 mutations have been reported in up to 50% of CRCs
(11) and are thought to arise late in the adenoma-carcinoma sequence. Normally, p53 is activated by a
wide range of cellular stressors including DNA damage, oxidative stress, heat or osmotic shock, and
oncogene activation (12). Following activation, p53 induces arrest of the cell cycle at the G1/S checkpoint.
If DNA repair is impossible, p53 can also initiate programmed cell death to eliminate the damaged cell
(12). Inactivation of p53 leads to the loss of these protective mechanisms and significantly increases the
risk of genomic damage and neoplastic transformation. In CRC, inactivation of p53 occurs most frequently
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as a result of loss of heterozygosity (LOH) of the short arm of chromosome 17 (11) followed by somatic
mutation of the remaining allele. 45% of the “second hits” to p53 occur within 5 “hotspots” (codons 175,
245, 248, 273, and 282) and are C->T transitions thought to result from the deamination of 5methylcytosine (11).
The majority of proto-oncogenes associated with CRC are involved in the mitogen-activated
protein kinase (MAPK) signaling pathway (13). The MAPK pathway is a signal transduction pathway that
communicates a mitogenic signal from cell-surface receptors to the nucleus in order to promote cell
division (14). Normally, signaling through this pathway is initiated by binding of an extracellular mitogen
to the cell-surface epidermal growth factor receptor (EGFR). EGFR activation facilitates the dissociation of
GDP from the small GTPase RAS, enabling GTP binding and RAS activation (14). RAS then activates the
kinase RAF, which phosphorylates MEK, which in turn activates MAPK. Finally, MAPK activates
transcription factors, such as MYC, which are translocated to the nucleus and effect changes to cell
physiology, including increased cell division (14). The MAPK pathway genes most commonly mutated in
CRC are KRAS and BRAF, which code for the small GTPase K-ras and the serine/threonine kinase B-raf.
KRAS and BRAF are mutated in 50% and 25% of human CRCs, respectively (13,15). These mutations are
thought to arise subsequent to APC mutations in the adenoma-carcinoma sequence (16). KRAS mutations
typically take the form of G>A transitions or G>T transversions (17) and impair GTPase activity, leading to
constitutive activation of K-ras. Similarly, BRAF mutations are typically T>A transversions in codon 600
that cause valine to be substituted with glutamate (V600E) in the protein activation domain, leading to
constitutive activation of B-raf (18). Mutations in both KRAS and BRAF lead to constitutive activation of
the MAPK signaling pathway and uncontrolled cellular proliferation.
While APC, TP53, KRAS and BRAF are among the genes most commonly mutated in human CRC,
there are mutations to many other genes that have been shown to be associated with human CRC (19).
Other frequently mutated genes include cell division control protein 4 (CDC4), an inhibitor of cell cycle
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progression, transforming growth factor beta 2 receptor (TGFβ2R) (20), and “deleted in colon cancer”
(DCC) (21). However, contributory mutations have been detected in a wide variety of genes, and it is
possible for CRCs to develop without acquiring the aforementioned mutations. In fact, a recent genomewide analysis by Vogelstein et al. (22) indicates that the average colorectal tumor carries between 2 and
8 mutations within a set of ~140 genes, all of which contribute directly to a selective growth advantage.
Furthermore, this study demonstrated that while these mutations affected three core cellular processes
(cell fate determination, cell survival, and genome maintenance), no two tumors shared identical
mutational profiles (22).

1.2.2 Epigenetic Alterations
In addition to the established series of mutational events that accompany the adenomacarcinoma sequence, a number of epigenetic aberrations have been identified in CRC, including altered
DNA methylation and covalent histone modifications (23). Furthermore, cancer-associated DNA
methylation changes have been found within normal colonic mucosa in patients without tumors,
suggesting that certain epigenetic defects may be characteristic of an epithelium that is predisposed to
neoplastic transformation (24,25). In CRC, aberrant DNA methylation predominantly takes two forms:
global hypomethylation, especially of transposable elements (26–28), and hypermethylation of CpG
islands within gene promoter regions (29,30). Global hypomethylation was the first cancer-associated
epigenetic defect to be discovered and is now recognized as a common feature of CRC (16). Cancerassociated DNA hypomethylation decreases overall genomic stability by increasing the risk of doublestranded DNA breaks, promoting the instability of repetitive sequences, and reactivating transposable
elements (31). In this way, DNA hypomethylation directly contributes to an increased mutational load.
Although

global

hypomethylation

was

discovered

earlier,

gene-specific

promoter

hypermethylation has been studied in CRC more extensively (29,30). Hypermethylation of CpG islands
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within gene promoter regions inhibits the binding of transcription factors and promotes the recruitment
of chromatin-remodeling complexes that cause the stabilization of condensed chromatin (32). These
changes lead to the transcriptional downregulation of genes coded within these chromatin regions in a
process known as “epigenetic silencing” (33). Several key tumor suppressor genes, including CDKN2A,
hMLH1, and CDH1 have been shown to be epigenetically silenced in CRC (29). Furthermore, preclinical
studies have demonstrated the requirement for de novo DNA methylation during intestinal adenoma
development (34,35). Deletion of DNA methyltransferase 1 and 3a (DNMT1, DNMT3a) has been shown by
Eads et al. (34) and Weis et al. (35), respectively, to prevent intestinal tumor formation in ApcMin/+ mice.
Site-specific hypermethylation can also cause gene expression imbalances by inducing loss of imprinting
(LOI) of parentally-imprinted loci (36). For example, Insulin-like Growth Factor 2 (IGF2), which is normally
expressed only from the paternal allele, is frequently overexpressed in CRC due to hypermethylation of
the IGF2/H19 imprinting control region (ICR) on the maternal allele, leading to aberrant transcriptional
activation (36). Thus, de novo methylation directly contributes to colorectal tumorigenesis both by
silencing tumor suppressors and by activating proto-oncogenes.
A subset of CRCs that exhibit hypermethylation of a particular set of genes have been described
as displaying a CpG island methylator phenotype (CIMP) (37). CIMP-associated CRCs appear to have
distinct molecular features (such as frequent BRAF mutation) (38), distinct histology (such as serrated
hyperplasia) (39), and distinct epidemiology (40), suggesting that they represent a clinically and
etiologically distinct class of tumor (40). The observation that many of the genes hypermethylated in
CIMP-positive CRCs have important tumor-suppressive functions led to the suggestion that CIMP tumors
arise via a pathway driven by promoter hypermethylation and epigenetic, rather than genetic, inactivation
of tumor suppressor genes (41,42). This “alternative pathway” (42) of colorectal carcinogenesis is now
generally accepted, and is believed to have implications for CRC prevention and therapy.
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CIMP is defined by hypermethylation of specific sets of genes that are referred to as “CIMP
panels”. The classical CIMP panel examines methylation of the genes MINT1, MINT2, MINT31, hMLH1,
and CDKN2A (43) and a tumor is considered to be CIMP-positive if it displays hypermethylation at ≥3 of
these loci. CIMP positivity has been shown to be associated with the presence of a BRAF mutation,
proximal tumor location, instability of microsatellite repeats (MSI) and a poor prognosis (44). Attempts
to refine the original CIMP panel have led to the development of a “new” CIMP panel that is comprised of
the genes CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 (44). This new panel has been shown to be
superior to the classical panel in the identification of CRCs harboring BRAF mutations and MSI, but has
inferior prognostic power (44). Notably, it has been shown that the prognostic power of both CIMP panels
is maximized when they are combined with analysis of MSI (44). While CIMP analysis has the potential to
improve personalized management of CRC, there is currently no consensus on a standardized panel for
the clinical identification of CIMP (44).
While epigenetic modifications in CRC have been thoroughly investigated, less is known about
their role in early neoplastic progression. Several studies have demonstrated aberrant DNA methylation
in colorectal adenomas (45,46). As shown by Luo et al. (45), adenomas exhibit considerable epigenetic
heterogeneity, but can be broadly classified into those with high-frequency methylation and those with
low-frequency methylation. Adenomas with a high frequency of aberrant methylation exhibited
methylation signatures similar to those of advanced CRC and had a low frequency of APC mutations,
suggesting that they might arise via a WNT-independent pathway (45). Studies from our laboratory (47)
and others (46,48,49), have even identified methylation defects associated with a limited set of genes
within human ACF. Chan et al. (48) showed that MINT1, MINT2, MINT31, and the tumor suppressor gene
CDKN2A, were frequently methylated in ACF from patients with synchronous CRC and that these
epigenetic modifications were strongly associated with KRAS codon 12 mutations. We later demonstrated
that the tumor suppressor gene RASSF1A is silenced by promoter hypermethylation in distal colon ACF,
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even in the absence of synchronous tumors (47). More recently, Inoue et al. (46) demonstrated that 6
genes are frequently hypermethylated in BRAF-mutant ACF, sessile serrated polyps (SSPs) and cancers
located in the proximal colon, providing additional evidence for the role of aberrant methylation in the
serrated pathway to CRC. Together, these observations suggest that aberrant DNA methylation patterns
may be established prior to adenoma formation and may be important for the promotion of early colonic
neoplasia. However, our limited understanding of the epigenetic alterations present in premalignant
lesions represents an important barrier to the development of new cancer detection and prevention
strategies.

1.2.3 Metabolic Reprogramming
While the first observations of dysregulated metabolism in cancer cells were made nearly a century
ago, studies over the last decade have revealed that tumorigenesis is dependent on extensive
reprogramming of cellular metabolism (50). This reprogramming affects many distinct metabolic
pathways, but a common consequence is a shift towards the generation of biosynthetic building blocks
and the ability to acquire necessary nutrients from a frequently nutrient-poor environment (50). These
changes enable a cancer cell to fulfill the biosynthetic demands associated with rapid proliferation (50). A
number of specific metabolic changes have been detected in CRCs with high frequency (51).
The first metabolic change to be identified in cancer cells was the increased uptake of glucose and the
preferential use of glycolysis to produce lactate, a phenomenon known as the “Warburg effect” (52).
Glycolysis is an inefficient means of ATP generation compared to oxidative phosphorylation, and so this
phenotype was originally thought to represent a defect in the mitochondrial machinery required for
oxidative energy production (53). However, recent studies have demonstrated that cancer cells have only
a modest increase in ATP consumption relative to their need for biosynthetic precursor molecules and
reducing equivalents in the form of NADPH (50). Glucose metabolism is a robust source of these
8

molecules, while the tricarboxylic acid (TCA) cycle, which generates ATP and NADH, is the major negative
regulator of glycolysis (54). Thus, uncoupling of glycolysis from the TCA cycle by converting glucose into
lactate prevents TCA cycle-mediated inhibition of glycolysis and enables the robust production of
biosynthetic precursors. This phenomenon has been observed in most cancer types, including CRC (55),
and has been used as the basis for several new imaging and therapeutic approaches.
Cancer cells upregulate the generation of biosynthetic precursors by diverting glycolytic intermediates
into several pathways that branch off from glycolysis. The first of these branching pathways is the pentose
phosphate pathway (PPP), which generates NADPH and ribose-5-phosphate, a critical structural
component of nucleotides (56). Proteins involved in the PPP have been shown to be almost ubiquitously
upregulated in CRC samples (57), suggesting that this pathway is enhanced in CRC. Furthermore,
pharmacologic inhibition of the PPP has been shown to be a viable strategy for CRC therapy (57). Perhaps
the best studied of the pathways that shunt metabolites out of glycolysis is the use of 3-phosphoglycerate
in the synthesis of serine as a means to generate methyl groups (50). Metabolic flux studies have
suggested that cancer cells may use as much as 50% of glucose-derived carbon in this pathway (58).
Proliferation of CRC cell lines has been shown to be inhibited by withdrawal of serine from the culture
media, and the growth of CRC xenografts is inhibited when mice are fed a serine- and glycine-free diet
(59), suggesting an increased demand for serine in these cells. Serine has a unique role as a substrate for
folate one-carbon metabolism (FOCM), which generates purine nucleotides and S-adenosylmethionine
(SAM), the main methyl donor used in DNA methylation reactions (60). Under normal conditions, cells use
methionine as the primary substrate for the generation of SAM, but are also able to use serine to generate
methionine via homocysteine remethylation under conditions of methionine starvation (61). However,
recent studies have shown that CRC cells utilize serine for the generation of methionine regardless of
methionine availability in the microenvironment, suggesting increased flux through FOCM and the
methionine cycle in CRC (61). Interestingly, methylene tetrahydrofolate dehydrogenase 2 (MTHFD2), a
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component of the FOCM arm used to generate nucleotides, was shown to be among the top three most
frequently overexpressed metabolic enzymes in all cancers (62), suggesting that alterations in FOCM may
be universal in tumorigenesis.
CRCs have also been shown to dysregulate various aspects of fatty acid metabolism. Early studies of
cancer cell lipid utilization revealed a shift towards the de novo synthesis of fatty acids (63) (which is
required for plasma membrane synthesis), cell growth, and proliferation. Using broad-spectrum
metabolite profiling, Williams et al. (64) have demonstrated that primary CRCs exhibit significantly
increased levels of many fatty acids, including phosphatidylcholine (PC), the primary plasma membrane
constituent. More recent evidence suggests that cancer cells are also capable of utilizing fatty acid
oxidation (FAO) as a means of energy production and that certain cancers, including CRC, may use this
mechanism preferentially (65,66). FAO is comprised of cyclical reactions that result in the shortening of
fatty acid hydrocarbon chains and the production of NADH, FADH2, and Acetyl-CoA in each round of
oxidation (66). NADH and FADH2 subsequently enter the electron transport chain (ETC) to produce ATP,
and Acetyl-CoA can be used in a variety of biosynthetic processes (66). By mass, fatty acids provide twice
as much energy as carbohydrates and are therefore the preferred substrate in situations that require
increased ATP production. This is exemplified by cancer cells undergoing loss of attachment (LOA) during
metastasis, in which glycolysis is inhibited and levels of ATP and NADPH are depleted (66). As shown by
Schafer et al. (67), activation of FAO increases levels of ATP and protects cancer cells from anoikis. FAO
dependence has been thoroughly documented in certain types of cancer, such as prostate cancer, and
has been validated as a viable therapeutic target (68). However, our understanding of the role of FAO in
CRC development is currently incomplete.
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1.3 Colorectal Cancer Prevention
1.3.1

Risk Factors

There are many genetic and environmental characteristics that can increase an individual’s lifetime
risk of developing CRC; these characteristics are referred to as “risk factors”. Risk factors can be largely
classified as “unmodifiable”, which are characteristics inherent to the individual that cannot be changed,
and “modifiable”, which can. Unmodifiable risk factors, such as a personal or family history of CRC, a
diagnosis of inflammatory bowel disease or an inherited cancer syndrome, and an individual’s ethnic
background, can all increase CRC risk. On the other hand, modifiable risk factors are typically behaviors or
consumption habits in which an individual knowingly (or sometimes unknowingly) partakes. Habits such
as cigarette smoking and heavy alcohol consumption are both strongly associated with CRC incidence, and
cessation of both behaviors is associated with clear reductions in risk (69,70). Obesity and a lack of physical
exercise have also been shown to increase CRC risk considerably (71,72). Finally, diet has been shown to
have a significant effect on the development of CRC, with diets high in fat, refined sugars, and red meat
increasing risk, and diets high in fruits and vegetables significantly decreasing risk (73).
The link between the consumption of foods that contain known carcinogens (e.g. alcohol and nnitroso compound-containing red meat) and CRC risk is particularly well established (74), and it has been
estimated that approximately 35% of human CRCs can be attributed to pro-carcinogenic compounds
present in the average diet (74). However, it is also known that an individual’s diet can be cancer
protective (75,76), and just as there are dietary components which are associated with an increased risk
of CRC, epidemiological studies have identified a large number of dietary constituents which are
associated with a decreased risk of CRC (77). Inverse relationships between intake of selenium, Vitamin
D3 and folic acid and CRC risk have been previously demonstrated (78,79). It has been proposed that
dietary components such as these may be useful as the basis for novel chemoprevention strategies (80).

11

1.3.2

CRC Screening
CRC develops slowly over the course of several decades. This slow development provides the

opportunity for the detection and removal of precancerous lesions and early-stage cancers. Currently, the
American College of Gastroenterology recommends routine endoscopic screening every 10 years,
beginning at age 50 (81). More frequent screening beginning at a younger age is recommended for
individuals with a personal history of CRC or adenoma, a first-degree relative with a history of CRC, a
diagnosis of IBD, or a hereditary cancer syndrome (81). Increased utilization of screening colonoscopy has
significantly reduced the incidence of CRC in the US, as well as associated morbidity and mortality, over
the last several decades (82). One study of approximately 2,600 individuals undergoing colonoscopy
between 1980 and 1990 found that mortality due to CRC was reduced by 53% after an average follow-up
period of 15.8 years (82). Colonoscopy is currently the preferred screening method due to its ability to
directly prevent CRC by the removal of precursor lesions (81).
Because CRC is rare in the average screening population, the most common positive outcome of
screening colonoscopy is the detection of a polyp, which is typically removed. Patients are stratified into
CRC risk categories according to the histopathologic features of polyps identified during colonoscopy. In
2012, the United States Multi-Society Task Force on CRC issued guidelines for postpolypectomy
surveillance (83), which updated a previous 2006 guideline. Patients with no polyps, or with only small
hyperplastic polyps in the rectum or distal colon, are instructed to return for surveillance colonoscopy
after 10 years (83). Patients in whom 1-2 small tubular adenomas or a single sessile serrated polyp are
detected are instructed to return in 5 years (83). All other patients, including those with >3 polyps, one or
more large tubular adenoma, one or more villous adenoma, one or more large sessile serrated adenoma,
or any polyp with high-grade dysplasia, are instructed to return for follow-up colonoscopy in 3 years’ time
(83). Finally, individuals with a diagnosis of FAP or HNPCC, or those who fit the clinical criteria for serrated
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polyposis syndrome, are recommended to undergo annual surveillance colonoscopy due to their high risk
of developing CRC (83).
Many additional approaches have been evaluated for their ability to reduce CRC morbidity and
mortality. Many of these alternate approaches are non-invasive and are thus the screening method
preferred by patients (84). Furthermore, these tests do not require the same degree of medical expertise
as colonoscopy and can frequently be self-administered, dramatically reducing costs associated with
screening. Thus, while routine colonoscopy remains the screening tool preferred by the American College
of Gastroenterology (81), it is thought that the availability of alternative approaches may encourage the
screening of individuals who might otherwise choose to dispense with screening altogether (81). Stool
blood tests, such as the fecal occult blood test (FOBT) and the fecal immunochemical test (FIT), are the
most commonly used non-invasive screening tests. These tests rely on the detection of CRC biomarkers–
measurable substances whose presence is indicative of a colonic tumor. The FOBT and FIT are used to
detect blood in the stool that is not detectable by eye. Blood detected in this way is non-specific, but may
indicate the presence of a tumor. The sensitivity of the FOBT is between 20 and 50%, but it has been
estimated that use of the FOBT reduces CRC mortality by 33% (85). More recently, tests designed to detect
cancer-specific molecular biomarkers have been approved by the FDA. Cologuard, a DNA test which
detects the presence of NDRG4 and BMP3 DNA methylation, as well as KRAS mutations, has shown
efficacy in CRC detection (86), though the long-term effects of this test on CRC morbidity and mortality
remain to be seen. Typically, a positive result of one of these tests requires follow-up colonoscopy to
confirm the presence of a tumor.

1.3.3

Aberrant crypt foci as surrogate markers for CRC

Aberrant crypt foci (ACF) are the earliest detectable abnormality in the colon and putative precursors
to CRC (87–89). ACF were originally discovered by Bird (90) in the colons of mice treated with the chemical
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carcinogen azoxymethane (AOM), and were later identified in humans during endoscopy (91). Subsequent
study of ACF revealed that they share many histologic and molecular features with adenomas and CRC
(47,48,88,89,91). ACF exhibit many of the same genetic abnormalities that are found in more advanced
lesions, including the mutations that are traditionally thought to arise early in the adenoma carcinoma
sequence. For these reasons, ACF are a promising candidate biomarker for CRC risk.
The histopathological characteristics of ACF can be variable, but ACF are broadly classified into two
categories: hyperplastic and dysplastic. Dysplastic ACF are characterized by abnormal proliferation within
the upper crypt, nuclear disorganization, and nearly complete loss of goblet cells differentiation (92).
Dysplastic ACF frequently exhibit KRAS mutations (88,93), and at least one study has reported a high
frequency of APC mutations (94), although this frequency may be exaggerated by the inclusion of FAP
patients in the study. Because of these histological and molecular features, dysplastic ACF are generally
accepted as the earliest precursor to CRC. Hyperplastic ACF display characteristics similar to hyperplastic
polyps and exhibit a high incidence of KRAS and BRAF mutations (88,93). Hyperplastic ACF can be further
sub-classified based on the presence or absence of serrated histology. Serrated ACF are defined by a
stellate luminal shape in cross-section with a prominent component of columnar crypts with
microvesicular cytoplasm (88). While hyperplastic ACF as a whole exhibit both KRAS and BRAF mutations,
BRAF alterations have been shown to be the predominant mutation associated with serrated hyperplastic
ACF, while KRAS mutations are more frequent in non-serrated ACF (88). While hyperplastic ACF were once
thought to lack APC mutations, it has recently been shown that APC mutations can be detected within
serrated ACF (94). Interestingly, serrated hyperplastic ACF have previously been shown to be associated
with cigarette smoking (95), suggesting a role for this risk factor in the etiology of serrated neoplasia.
While dysplastic ACF are generally accepted as a precursor to CRC, there is controversy surrounding the
role of hyperplastic ACF in colorectal carcinogenesis. Thus, it will be important to fully characterize the
genetic alterations that are present in hyperplastic ACF to better understand the myriad pathways to CRC.
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1.3.4 Chemoprevention of CRC
While screening and surveillance remain the most effective strategies for CRC prevention, there
has been growing interest in the use of chemoprevention as a complementary strategy for CRC risk
reduction. Chemoprevention is the use of pharmacologic or natural agents to inhibit the development of
carcinoma by preventing the neoplastic transformation of normal cells, or by arresting or reversing the
progression of existing premalignant cells. A large number of natural and synthetic agents have been
evaluated for their ability to prevent CRC including non-steroidal anti-inflammatory drugs (NSAIDs), folic
acid, calcium, vitamin D, and various anti-oxidants (96). The chemopreventive efficacy of most of these
agents remains controversial (96), however, there is good evidence to support the use of certain agents
within specific contexts. NSAIDs, especially those that inhibit the enzyme cyclooxygenase-2 (COX-2), such
as aspirin, have shown the ability to reduce the incidence of adenomas and CRC in the general population
(96) and have been shown to reduce polyp recurrence in individuals with FAP (96). Recently, the United
States Preventive Services Task Force (USPSTF) issued a recommendation that aspirin be used for the
prevention of CRC in individuals over the age of 50 who are also at an increased risk of cardiovascular
disease (97). There is also evidence that calcium supplementation may reduce the risk of adenoma
recurrence in individuals with increased risk of CRC, such as those with a personal history of adenoma
(96).
Unfortunately, many chemopreventive agents have failed to show efficacy in randomized
controlled trials (RCTs), or have had positive RCT results called into question by large meta-analyses. These
failures have caused some to question the validity of cancer chemoprevention, even going so far as to
claim that chemoprevention causes more harm than good (98). However, advocates of chemoprevention
argue that the failure of chemopreventive interventions in large RCTs of human subjects pulled from the
general population underscores the need to test the right agents, in the right doses, in the right
populations (99). In fact, many chemoprevention trials have failed to examine the efficacy of a given agent
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in a population that reflects the preclinical model in which that agent originally demonstrated promise
(99). It will be important for future chemoprevention studies to match interventions to the specific
subpopulations who stand to benefit most. Furthermore, it will be important to understand how the best
chemoprevention strategy for a particular individual may change over time in order to adapt to changes
in diet, age, and personal history of neoplasia. In order to fully realize the potential of CRC
chemoprevention, novel strategies should be tailored to an individual’s unique risk profile.

1.4 Folate One-Carbon Metabolism (FOCM)
1.4.1

FOCM and CRC Risk
Over the last few decades there has been increased interest in how an array of dietary

components may affect cancer progression and whether any of these components have potential for use
as chemopreventive agents. Folate, also known as vitamin B9, has been the subject of numerous studies
seeking to understand its role in cancer progression (100–105). This is due, in part, to the 1996 mandate
by the United States Food and Drug Administration (FDA) requiring the supplementation of wheat, rice,
bread, cereals, pasta and other grain products with folic acid in an effort to reduce the incidence of neural
tube birth defects (106). Following this mandate, several studies were published that put forth conflicting
findings regarding the influence of folate supplementation on colorectal cancer (CRC) progression; nearly
two decades later the debate over whether folate promotes or prevents CRC continues. The controversy
surrounding the influence of folate on tumorigenesis is likely due to its position at the center of a complex
metabolic network that controls a variety of biological processes including nucleotide synthesis, DNA
integrity, and epigenetic regulation of gene expression (107,108). It is because of folate’s involvement in
many biological processes relevant to cancer development, and its potential to modulate these processes,
that it has been widely considered for its potential chemopreventive benefit. However, despite significant
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potential and a large body of research into its multifaceted functions, understanding of the intricate
effects of folate intake and supplementation on cancer risk remains elusive.
The earliest investigations into the relationship between folate and CRC risk were epidemiological
case-control studies examining associations between CRC incidence and folate intake determined from
dietary questionnaires. Three such studies that were among the first to report on folate intake and CRC
risk demonstrated an inverse relationship between folate consumption and CRC incidence (101,109–111).
Importantly, all three of these studies were conducted in countries that, at the time, had not implemented
folic acid fortification programs and were therefore more likely to have higher incidence of inadequate
folate intake. For the most part, studies of folic acid intake and the risk of colorectal neoplasia conducted
in the United States after the implementation of the national fortification program have also supported
an inverse relationship between intake and risk in the general population (112–114). However, several
key studies have challenged this long-standing paradigm. A recent meta-analysis of 50,000 individuals
enrolled in 13 different folate supplementation trials failed to show a significant effect of folate intake on
CRC risk in the general population (115). Furthermore, several randomized controlled trials of folate
supplementation have suggested that elevated folic acid intake may actually increase CRC risk in certain
high-risk subpopulations (116,117). As shown by Cole and Baron (118), folic acid supplementation (1mg/d)
in individuals with a history of colorectal adenoma significantly increases the incidence of advanced
lesions at 3-year follow-up. Additionally, a more recent meta-analysis of six large folic acid
supplementation trials has concluded that folic acid supplementation is associated with an increased risk
of cancer (119).
In contrast to many epidemiologic studies, studies in rodent models have suggested that folate
deficiency slows tumor progression when it is initiated after the establishment of preneoplasia (120–122).
As a result, it has been suggested that folic acid may have a “dual modulatory effect” on carcinogenesis
(123); prior to the establishment of neoplastic lesions, high folate intake decreases the risk of cancer,
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while high folate intake after the establishment of neoplasia drives progression. Thus, within the context
of folate-based chemoprevention strategies, careful consideration of dosage and timing with respect to
carcinogenic initiation are critical determinants of the safety and efficacy of an intervention. Furthermore,
these data suggest that certain high-risk human populations, such as individuals with a personal history
of colonic neoplasia, or those with a heritable CRC syndrome, may benefit from reduced folate intake.
Thus, improved understanding of the effects of dietary folate modulation on CRC pathogenesis may lead
to the development of novel strategies for CRC prevention and treatment.

1.4.2

Molecular Biology of FOCM
Folic acid metabolites are used as substrates in the biosynthesis of both thymidylate and purine

nucleotides. Once folate has entered the cell, it is reduced to tetrahydrofolate (THF), which acts as the
central nexus of FOCM (Figure 1-1). THF undergoes a series of enzymatic conversions, with each step in
the pathway giving rise to an intermediate that serves a unique role. The most important folate derivatives
for nucleotide metabolism are 5,10-Methylene THF and N10-Formyl THF. 5,10-Methylene THF is the
substrate for the enzyme thymidylate synthase (TS) which transfers a methyl group from 5,10-Methylene
THF to deoxyuridine monophosphate (dUMP) to generate thymidine monophosphate (dTMP) (124). N10Formyl THF, on the other hand, is the substrate for two enzymes involved in separate steps in the
biosynthesis of purine nucleotides: Phosphoribosylglycinamide formyltransferase (GART) and
phosphoribosylaminoimidazolecarboxamide formyl transferase (AICARFT) (125,126). GART transfers a
methyl group from N10-formyl THF to glycinamide ribonucleotide (GAR) to generate the purine
intermediate N-formylglycinamide ribonucleotide (FGAR). Later in the purine biosynthetic pathway,
AICARFT transfers another carbon from N10-formyl THF to AICAR to generate the purine intermediate 5formamidoimidazole-4-carboxamide ribonucleotide (FAICAR) (Figure 1-1) (127). Thus, the supply of folate
is incredibly important for nucleotide biosynthesis, as it is the primary source of crucial structural carbons
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Figure 1-1. Folate One-Carbon Metabolism (A) Overview of folate metabolism. Dietary folate is converted
into several key metabolites by a series of enzymatic conversions. (B) 5,10-Methylene Tetahydrofolate is
used as the substrate for thymidylate synthesis, where a methyl group is donated to deoxyuridine
monophosphate

(dUMP)

to

form

deoxythymidine

monophosphate

(dTMP). (C) 10-Formyl

Tetrahydrofolate performs a similar function in the synthesis of the purine nucleotide precursor, inosine
monophosphate (IMP). Initially, 10-FTHF donates a formyl group to convert glycinamide ribonucleotide
(GAR) to N-formylglycinamide ribonucleotide (FGAR). In a later step, 10-FTHF donates a formyl group to
convert 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) into 5-Formamidoimidazole-4carboxamide ribotide (FAICAR). (D) Methyl groups can be shuttled from 5-Methyl Tetrahydofolate (5MTHF) to the homocysteine cycle, where they are used to regenerate the “universal methyl donor”, Sadenosyl methionine (SAM). SAM in turn serves as the substrate for the DNA methyltransferase enzymes,
which transfer a methyl group from SAM to cytosine, resulting in the formation of 5-methylcytosine.
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Figure 1-1
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in purine precursors and of the carbon that is necessary to convert dUMP to dTMP. Imbalances in these
key folate metabolites have previously been detected in colorectal tumors, underscoring the relevance of
this metabolic pathway to colon carcinogenesis (128).
It is folic acid’s role in nucleotide metabolism that has made it an interesting chemopreventive
candidate from a mechanistic standpoint. It has been hypothesized that folate deficiency causes DNA
damage by reducing the availability of nucleotide synthesis precursors and thus causing an imbalance in
nucleotide pools (129). However, this same mechanism might help to explain the inhibitory effect of folate
deficiency on the growth of established neoplasia. Cells which have undergone transformation tend to
have a higher rate of replication and a higher demand for nucleotides than their comparatively slowreplicating normal counterparts. In transformed cells, low folate status places a severe restriction on
nucleotide biosynthesis, inhibiting DNA replication and slowing tumor growth (130). A recent study by
Witherspoon (131) revealed that the chemopreventive agent -difluoromethylornithine (DFMO) exerts
its protective effects by altering the availability of folate derivatives, supporting this hypothesis.
A second mechanism through which folate intake has been proposed to offer chemopreventive
benefit is the modulation of DNA methylation. The supply of one-carbon groups used in methylation
reactions is dependent on metabolic flux through the methionine cycle (132), which generates SAM, the
“universal methyl donor”. Dietary folic acid is eventually converted to the metabolite 5methyltetrahydrofolate (5-MTHF); a methyl group is then transferred to homocysteine to generate
methionine, which reacts with ATP to generate SAM. SAM is the substrate for DNMTs, which transfer a
methyl group to DNA CpGs, converting SAM to S-adenosyl homocysteine (SAH) and the target cytosine to
5-methylcytosine (Figure 1-1) (133). The availability of SAM and SAH are important regulators of DNMT
activity and the maintenance of patterns of DNA methylation. Considering the importance of folate for
homocysteine metabolism and DNA methylation, it has been suggested that folate-based
chemoprevention may help to maintain normal patterns of methylation (108,134,135).
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While nucleotide biosynthesis and DNA methylation are the best-characterized folate-dependent
molecular mechanisms, steps still need to be taken to understand how the role of FOCM in cancer risk
changes throughout the carcinogenic process. As a cell acquires more genomic changes and progresses
towards cancer its metabolic demands change. This should be taken into account when considering a
biosynthesis-based mechanism of folate chemoprevention.
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1.5 Specific Aims
Aim 1: To characterize the landscape of aberrant DNA methylation in human colonic preneoplasia
ACF are the earliest detectable abnormality in the colon and putative precursors to CRC that share
many histologic and molecular abnormalities with colonic adenomas and carcinomas. While extensive
epigenetic modifications are a common feature of CRC, their role in early neoplastic progression is less
well defined. To address this deficit, we will use an integrative genomic approach to identify functional
DNA methylation changes in human ACF. We will combine laser-capture microdissection (LCM) with
reduced-representation bisulfite sequencing (RRBS) and whole-genome RNA sequencing (RNA-Seq) to
characterize changes to DNA methylation and gene expression in a set of 10 ACF and 10 Stage III-IV
primary CRCs. These data will contribute to a more in-depth understanding of the DNA methylation
changes that are present in early colonic neoplasia, and may lead to the identification of new targets for
CRC detection and prevention.

Aim 2: To evaluate the preventive efficacy of temporary dietary methyl donor deficiency
Folate one-carbon metabolism (FOCM) is the metabolic system that converts a group of nutrients
referred to as “methyl donors” into one-carbon moieties that are used in nucleotide biosynthesis and DNA
methylation. Disruption of FOCM has been used successfully for many years as a strategy to treat CRC.
However, less is known about how disruption of FOCM via manipulation of dietary methyl donors can be
used to prevent colorectal carcinogenesis. We have previously shown that a diet deficient in the methyl
donors folate, choline, methionine and vitamin B12 is able to suppress tumor formation in ApcMin/+ mice.
In this aim, we will extend our previous studies by examining the effects of dietary methyl donor deficiency
(MDD) in a mouse model with an Apc truncation mutation more typical of that found in human cancers
and a higher prevalence of colon tumor development. Furthermore, we will specifically determine
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whether temporary MDD, followed by re-feeding with a methyl donor sufficient (MDS) diet, is capable of
providing long-lasting tumor protection while reversing unwanted side effects.

Aim 3: To define the metabolic changes associated with MDD cancer protection
We have previously demonstrated that a MDD diet protects against tumor formation in ApcMin/+
mice. At present, the metabolic pathways through which the MDD diet affects changes to the intestinal
epithelium and reduces CRC risk are unknown. We will use an untargeted metabolomic profiling platform
to quantify ~400 biochemicals within samples of colonic mucosa collected from mice in Aim 2. We will
then employ pathway analysis to identify the specific metabolic pathways that are critical to the protective
effects of MDD. In addition, we will identify any metabolic changes that persist beyond temporary
administration of the MDD diet. These data will provide clues to the molecular changes underlying MDDinduced tumor protection and identify metabolomic features of the MDD diet that may provide new
targets for CRC prevention.
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Chapter 2: Genome-wide methylation profiling reveals cancer-associated changes within
human early colonic neoplasia
2.1 Introduction
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths in the U.S (1). In
addition to the established series of mutational events that accompany the adenoma-carcinoma
sequence, a number of epigenetic aberrations have been identified in CRC, including altered DNA
methylation and covalent histone modifications (23). Global DNA hypomethylation, first identified in
cancers more than three decades ago, is now recognized as a common genetic feature of CRC (26). DNA
hypomethylation promotes genomic instability (27), in many cases leading to an increased mutational
load and activation of proto-oncogenes (27). On the other hand, gene-specific promoter
hypermethylation has been shown to promote CRC by silencing the expression of key tumor suppressor
genes such as CDKN2A, hMLH1 and CDH1 (29).
While extensive epigenetic modifications are a common feature of CRC, their role in early
neoplastic progression is less well defined. As reviewed by Sakai et al. (30), changes to DNA methylation
have been found at early stages of cancer development, particularly in colorectal adenomas. Specific DNA
methylation changes have even been found within normal colonic mucosa of patients with CRC (24,25),
suggesting the possibility that epigenetic defects may predict subsequent cancer risk. Aberrant crypt foci
(ACF) are the earliest morphologically identifiable mucosal abnormality in the colon, a subset of which
may be precancerous and contribute to a “field defect” within the mucosa (136). Studies from our
laboratory (47) and others (48,49) have identified methylation defects associated with human ACF,
including the silencing of tumor suppressor genes by promoter hypermethylation. An early study by Chan
et al. (48) showed that MINT1, MINT2, MINT31, and the tumor suppressor gene CDKN2A, were frequently
methylated in ACF from patients with synchronous CRC. This study further reported that increased DNA
methylation in ACF was strongly associated with the presence of KRAS codon 12 mutations (48). We later
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demonstrated that the tumor suppressor gene RASSF1A is silenced by promoter hypermethylation in
distal colon ACF, even in the absence of synchronous tumors (47). These observations suggest that
aberrant DNA methylation patterns may be established prior to adenoma formation and may be
important for the promotion of early colonic neoplasia.
Our limited understanding of the molecular alterations present in premalignant lesions represents
an important barrier to the development of new cancer detection and prevention strategies (137). To
address this issue, the present study was undertaken to develop a more in-depth understanding of the
DNA methylation changes that are present in human ACF. To achieve the requisite sensitivity for analysis
of isolated colonic epithelial cells, we combined reduced representation bisulfite sequencing (RRBS) with
laser-capture microdissection (LCM) of ACF harboring mutations in exon 2 of the KRAS oncogene. RRBS is
an efficient, high-throughput sequencing technique that combines sodium bisulfite conversion of
unmethylated cytosines with MspI restriction digestion to enrich samples for CpG-rich regions of the
genome (138). Using this approach, we have shown that KRAS-mutant ACF harbor extensive DNA
methylation changes, many of which are also present in primary CRCs. ACF-associated methylation
changes were enriched for genes involved in cellular identity and differentiation, a set of genes targeted
by the Polycomb Repressive Complex 2 (PRC2), and genomic regions containing AP-1 transcription factor
binding sequences. These observations extend the scope of aberrant methylation in the earliest stages of
colonic neoplasia and define features of an epigenomic landscape that may provide new targets for CRC
detection and chemoprevention.

2.2 Materials and Methods
Subject selection and human tissue collection
All ACF subjects included in this study were enrolled in an ongoing clinical study at John Dempsey
Hospital (UConn Health). All patients who met the Amsterdam criteria for familial adenomatous polyposis
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(FAP) or hereditary non-polyposis CRC (HNPCC) were excluded from this study. In order to control for the
effects of age and smoking on DNA methylation, all selected subjects were non-smokers between the ages
of 50 and 65. 10 ACF were biopsied from the distal colons of individual subjects as previously described
(88). Briefly, ACF were identified and biopsied during high-definition, magnifying chromoendoscopy using
indigo carmine dye-spray (88). For each subject, a sample of normal-appearing mucosa was also obtained
from the distal colon. Biopsies were immediately embedded in OCT freezing medium (Neg 50,
ThermoFisher Scientific), flash-frozen, and stored at -80C. Frozen tissues were sectioned onto
polyethylene naphthalate (PEN, ThermoFisher Scientific) membrane slides using a Leica CM1900 Cryostat.
Frozen sections were stained with hematoxylin and eosin (H&E) and routine histologic analyses were
performed. All biopsies collected from ACF subjects were histologically confirmed by a board-certified
human gastrointestinal pathologist blinded according to previously established criteria (88).
Ten Stage III-IV CRCs resected from the distal colons of individual subjects were obtained from
the City of Hope frozen tumor bank. In addition, 10 histologically-confirmed matched normal samples,
collected from the margins on either side of the resected tumor, were obtained. Tissue sections were
stained with H&E and reviewed by a board-certified pathologist to confirm the presence and
histopathology of the lesions. This study was conducted with the written informed consent of each
subject, as well as Institutional Review Board approval from both the University of Connecticut Health and
City of Hope (IRB Protocols IE-10-068OSJ-3 and 97134, respectively).

Laser-capture microdissection
LCM of ACF and matched normal biopsies was performed as previously described (88). Briefly, an
ArcturusXT Laser Capture Microdissection system was used to isolate a minimum of 1 mm 2 of tissue
(~5000 cells) from 12 µm-thick frozen serial sections. LCM caps were stored at -80C until nucleic acid
extraction.
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DNA methylation profiling and mutation screening
Genomic DNA was isolated from laser-captured colonic crypt epithelium using phenol/chloroform
extraction. KRAS Exon 2 was amplified by PCR using targeted primers (5’GGTCCTGCACCAGTAATATG and
5’AACCTTATGTGTGACATGTTCTAA) and sequenced at the City of Hope Integrative Genomics Core using
Sanger sequencing. Only ACF and cancer samples with a mutation in KRAS Exon 2 (KRASG12D or KRASG12V)
were selected for further analysis by RRBS. RRBS was done as previously described (139). Briefly, purified
DNA was digested by overnight incubation with MspI at 37°C. Following restriction digest, DNA fragments
were subjected to end repair and A-tailing, followed by linker ligation. Bisulfite conversion was done using
the EZ DNA Methylation-Gold Kit (Zymo Research) according to the manufacturer’s instructions. RRBS
libraries were sequenced on the HiSeq 2500 (Illumina) using 100 bp paired-end sequencing according to
the manufacturer’s protocol. A minimum of 14 million reads/sample were aligned to human reference
genome assembly hg19. For RRBS analysis, genomic regions were defined as sequences containing a
minimum of 2 CpGs separated by no more than 100 bp. Differentially methylated regions (DMRs) were
defined as genomic regions exhibiting an average change in methylation ≥15% compared to matched
normal, with a false discovery rate (FDR)-adjusted p-value < 0.05. Bootstrapping analysis was performed
as a control for the identification of overlapping DMRs by generating 1,000 sets of 811 randomly selected
DMRs, calculating the average number of overlapping DMRs in these sets and comparing the expected
value to the observed number of overlapping DMRs. As shown in Figure 2-1, data obtained using RRBS
from independent sequencing runs were highly reproducible.
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Figure 2-1. Internal controls for reduced representation bisulfite sequencing and RNA-Seq analysis. (A)
Parallel RNA sequencing runs of two independent library preparations from the same ACF sample show a
high correlation between the number of successfully mapped reads per genomic region. (B) Correlation
between multiple sequencing runs from the same library for 2 ACF and 2 samples of normal colonic
mucosa. Correlation coefficients were calculated for the total number of successfully mapped reads for
individual CpGs with a minimum of 10 mapped reads, excluding those within Msp1 restriction sites
(CCGG).
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Transcriptome profiling
RNA was isolated from cancer samples using the mirVana miRNA Isolation Kit (Ambion) and from
laser-captured ACF samples using the Arcturus PicoPure Frozen RNA Isolation Kit (ThermoFisher)
according to the manufacturers' instructions. Sequencing libraries were prepared from RNA isolated from
cancer samples using the TruSeq Stranded Total Library Preparation Kit and the RiboZero Gold rRNA
Removal Kit (Illumina). For RNA extracted from ACF, depletion of rRNA was done using the RiboZero
Magnetic Kit according to the “Protocol for Removal of rRNA from Small Amounts of Total RNA”
(Clontech). Subsequently, dscDNA library preparation and amplification were done using the SMARTer
Stranded RNA-Seq Kit (Clontech) according to the manufacturer's protocol. RNA sequencing for both
sample types was done on the HiSeq 2500 (Illumina) using 40-bp paired-end sequencing according to the
manufacturer’s protocol. A minimum of 40 million reads/sample were aligned to the human reference
genome assembly hg19. As shown in Figure 2-1, data obtained using RNA-seq from two independent
library preparations were highly reproducible

Bioinformatics Analysis
Gene ontology (GO) analysis was conducted using the Database for Annotation, Visualization, and
Integrated Discovery (DAVID) according to standard protocol (140). Briefly, GO analysis was done using
the statistical overrepresentation test with Bonferroni correction for multiple testing. Gene set
enrichment analysis (GSEA) was performed by calculating the overlap of gene sets of interest with
annotated gene sets stored in the Molecular Signatures Database (MSigDB) version 5.1 (Broad Institute,
Cambridge MA)(141). Comparison of DMRs to H3K27Ac-marked enhancer regions was done using
ENCODE dataset ENCSR327XTS. Hypergeometric Optimization of Motif EnRichment (HOMER) analysis
(142) was used to evaluate the enrichment of known transcription factor binding motifs located within
differentially methylated regions of the genome. Bootstrapping analysis was performed as a control for
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HOMER by generating 1,000 sets of 297 randomly selected intergenic regions, calculating the expected
percent enrichment for motifs of interest and comparing this value to the observed percent enrichment.

Statistical Analysis
The set of genomic regions with frequently altered DNA methylation was subjected to complete linkage
clustering using a Euclidean distance measure. Correlation between changes in promoter methylation and
changes in gene expression were estimated by Pearson’s correlation analysis. Statistical analyses of
differentially methylated regions (DMRs) and differentially expressed genes were performed using
Student’s t-test followed by false discovery rate (FDR) correction using the Benjamini-Hochberg
procedure. Principal component analysis (PCA) and biplot generation were done using the R programming
language and software environment.

2.3 Results
Genome-wide DNA methylation changes in colon cancers and ACF
To investigate the epigenomic landscape of early colonic neoplasia, RRBS analysis was used to
identify DNA methylation changes in stage III-IV CRCs and ACF biopsied from the distal colon;
representative images of an ACF visualized during endoscopy and its histological appearance are shown
in Figure 2-2A. Differentially methylated regions (DMRs), defined as genomic regions exhibiting an
average change in methylation ≥ 15% compared to matched normal that achieved a false-discoveryadjusted p-value < 0.05, were used for all subsequent analyses. The heat-map shown in Figure 2-2B,
generated by unsupervised clustering, shows DMRs identified in CRC. A total of 23,745 DMRs were
identified, consistent with previous reports that aberrant DNA methylation is a common feature of CRC
(30). 5,995 (25%) of these DMRs were hypermethylated, while 17,750 (75%) were hypomethylated.
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Figure 2-2. DNA methylation patterns in Stage III-IV CRCs and ACF. (A) (Top) Gross appearance of a
human ACF during endoscopic screening. (Bottom) H&E-stained slide showing an ACF biopsy with serrated
morphology. Serrated crypts, characterized by star-shaped lumen in cross section, are indicated with black
arrows. (B) Heat-map depicting differentially methylated regions (DMRs), defined as genomic regions with
a change in methylation relative to matched normal >15% and a FDR-adjusted P-value<0.05, in colon
cancer samples. In general, tumor samples are segregated from normal mucosa by unsupervised
clustering, indicating distinct methylation profiles. Of the 23,745 DMRs detected in cancer samples, 5,995
(25%) were hypermethylated while 17,750 (75%) were hypomethylated, indicating a trend towards
decreased global methylation. (C) Heat-map depicting DMRs in ACF. In general, ACF are segregated from
normal mucosa samples by unsupervised clustering, indicating distinct methylation profiles. 811 DMRs
were identified, 537 (66%) of which were hypermethylated and 274 of which (34%) were hypomethylated,
indicating a trend towards increased global methylation that contrasts the global methylation status of
cancer samples.
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Methylation changes were also found in ACF (Figure 2-2C); 811 regions were differentially
methylated compared to matched normal mucosa. However, in ACF, 537 (66%) of these DMRs were
hypermethylated, while only 274 (34%) were hypomethylated, indicating an increase in global
methylation. The difference in net methylation change between ACF and CRC suggests that a shift in global
methylation status may be important for progression from early neoplasia to invasive CRC.
To gain a better understanding of the functional significance of methylation changes found in ACF,
GSEA was used to compare the set of all ACF DMRs to annotated functional gene sets stored in the
Molecular Signatures Database (Broad Institute, Cambridge, MA) (141). GSEA identified enrichment for
transcription factors involved in intestinal development, including CBFA2T2, FOXF1, NKX2-3, NOTCH1,
PAX6, and PDGFA (Figure 2-3) (143–148). In addition, this set of genes was enriched for targets of PRC2
identified in human embryonic stem cells (hESCs) (149). PRC2 is a chromatin-remodeling complex involved
in the maintenance of stem cell plasticity (150). Furthermore, ACF-associated DMRs showed enrichment
for genes known to be trimethylated at lysine 27 of histone subunit 3 (H3K27me3, the “polycomb mark”)
in normal adult colonic mucosa (151). Finally, genes with frequent methylation changes in ACF contained
a number of HOX genes (HOXA3, HOXC9, HOXC10, HOXC11, and HOXC13), a family of early developmental
regulators whose aberrant expression has previously been implicated in human carcinogenesis (152).
These findings demonstrate that genes involved in normal intestinal development and genes targeted by
PRC2 in embryonic stem cells frequently exhibit methylation changes in human ACF and suggest a role for
the epigenetic disruption of these genes in the establishment of early neoplasia.
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Figure 2-3. Representative sequencing tracks showing aberrant methylation of genes involved in normal
intestinal development. DMRs associated with these genes tended to overlap with H3K27Ac peaks
identified in normal colonic mucosa, suggesting that they occur within active enhancer regions. H3K27Ac
data was obtained from the ENCODE project (Accession: ENCSR327XTS).
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Cancer-associated methylation changes are present in ACF
In the following analyses, methylation profiles of DMRs present in CRCs and ACF samples were
normalized to matched normal-appearing mucosa. As shown in Figure 2-4A, data were clearly separated
by PCA, indicating distinct methylation profiles, although ACF showed tighter overall clustering than
tumors. Despite segregation by PCA, a subset of genomic regions was classified as DMRs in both cancer
and ACF samples (Figure 2-4B). Of these shared DMRs, the majority exhibited methylation changes in the
same direction (66% hypermethylated, 32% hypomethylated) and are referred to as “overlapping” DMRs.
In general, these methylation changes were of greater magnitude in cancers than in ACF, regardless of the
direction of change or the genomic location of the altered region.
As shown in Figure 2-5A, 592 DMRs were classified as overlapping. Bootstrapping analysis
confirmed that this degree of overlap between ACF and CRC DMRs was highly significant (Figure 2-5B).
Approximately 75% of all DMRs identified in ACF overlapped with CRC DMRs. Hypermethylated
overlapping DMRs were evenly distributed among promoters (139, 35%), gene bodies (147, 37%) and
intergenic regions (113, 28%) (Figure 2-5C). In contrast, hypomethylated overlapping DMRs occurred
mainly within gene bodies (84; 44%) and intergenic regions (104; 53%); only 5 (3%) were located in
promoter regions (Figure 2-5C). As shown in Figure 2-6A, GSEA revealed that overlapping DMRs were
frequently associated with homeobox genes. As shown in Figure 2-6B, overlapping DMRs associated with
homeobox genes were frequently hypermethylated.

Non-promoter DMRs undergo a switch in methylation status during cancer development
To better define the methylation landscape of early and late colonic neoplasia, all DMRs were
separated according to their genomic location into gene body, intergenic, and promoter DMRs. 8,849
(37%) cancer-associated DMRs were located within gene bodies, 12,170 (51%) were located in intergenic
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Figure 2-4. Direct comparison of DNA methylation changes in Stage III-IV CRCs and ACF. (A) Principal
component analysis (PCA) biplot of DNA methylation changes demonstrates a clear segregation of ACF
(red) and tumor samples (black), indicating distinct aberrant methylation profiles. CRC samples are less
tightly clustered than ACF samples, suggesting greater variability within cancer samples. (B) Heat-map
depicting DMRs detected in both ACF and CRC. Of 608 shared DMRs, 66% were hypermethylated and 32%
were hypomethylated; a small subset of DMRs (2%) were hypermethylated in ACF but hypomethylated in
cancer. Notably, the magnitude of these overlapping changes was typically greater in CRC than in ACF.
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Figure 2-5. Genomic distribution of “overlapping” DMRs. (A) 592 DMRs exhibited a methylation change
in the same direction in both stage III-IV cancers and ACF; these DMRs are referred to as “overlapping”
DMRs (B) Histogram depicting the results of bootstrapping control analysis for overlapping DMR analysis.
On average, randomly generated genomic region sets contained 9.6 ± 3.1 overlapping DMRs, significantly
fewer than the 592 observed real overlapping DMRs (P<0.001), indicating that the probability of
identifying these overlapping DMRs by random chance is very low. (C) Distribution of the genomic location
of DMRs with altered methylation identified in both ACF and CRC. Overlapping hypermethylated DMRs
were evenly distributed amongst promoters (35%), gene bodies (37%) and intergenic regions (28%).
Overlapping DMRs exhibiting hypomethylation were rarely located within promoters (3%), but were
common in gene bodies (44%) and intergenic regions (53%). (D) Distribution of the genomic location of all
DMRs (increased and decreased methylation) in ACF and CRC. While the genomic distribution of DMRs
identified in ACF was very similar to the distribution of all sequenced regions, DMRs identified in cancer
samples exhibited a bias towards non-promoter localization.
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Figure 2-5
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Figure 2-6. Functional enrichment analysis of overlapping DMRs. (A) GO results for overlapping DMRs.
Overlapping DMRs were significantly enriched (FDR-adjusted P-value <0.05) for homeobox genes, as well
as genes involved in the regulation of transcription and cell fate commitment. (B) Selected representative
homeobox genes with increased methylation in both ACF and cancer. All of the genes shown here exhibit
significantly increased methylation in both ACF and cancer samples compared to matched normal tissues;
notably, the magnitude to which methylation is increased tends to be greater in cancer than in ACF. Error
bars represent SEM.

39

regions, and 2,726 (11%) were located within known promoter regions, indicating more extensive
methylation changes within non-promoter regions in CRC (Figure 2-5D). Similarly, of the 811 DMRs found
in ACF, 349 (43%) were located within gene bodies, 297 (37%) were located in intergenic regions, and 165
(20%) were located within promoters (Figure 2-5D).
In cancers, DMRs in non-promoter regions were primarily hypomethylated compared to matched
normal; 6,591 (74%) gene body-associated DMRs were hypomethylated (Figure 2-7A) and 10,401 (85%)
intergenic DMRs were hypomethylated (Figure 2-7B). In contrast, 213 (61%) gene body-associated DMRs
were hypermethylated (Figure 2-7A) and 168 (57%) intergenic regions were hypermethylated (Figure 27B) in ACF samples. Together, these results suggest that genome-wide DNA hypomethylation occurs
during later stages of CRC progression. In contrast to gene bodies and intergenic regions, the majority of
promoter DMRs in both cancers (1,968, 72%) and ACF (165, 95%) were hypermethylated (Figure 2-7C).

Intergenic DMRs are enriched for AP-1 family transcription factor binding motifs
As shown in Figure 2-5D and Figure 2-7B, a significant fraction of ACF and cancer DMRs were
located in noncoding intergenic regions of the genome. To determine whether these DMRs were enriched
for regulatory features, we used Hypergeometric Optimization of Motif EnRichment (HOMER) analysis
(142) to identify sequence elements within DMRs that correspond to known transcription factor binding
motifs. As shown in Figure 2-8A, intergenic DMRs in CRCs were enriched for 103 motifs, including 6 that
were also enriched in ACF intergenic DMRs. Furthermore, a number of motifs were also enriched in DMRs
located within gene bodies in cancer samples. As shown in Figure 2-8B, bootstrapping analysis indicated
that these results were highly statistically significant. As shown in Figure 2-8C, 5 of the 6 motifs enriched
in ACF intergenic DMRs corresponded to binding sequences for AP-1 family transcription factors. The
majority of DMRs enriched for AP-1 motifs were hypomethylated in both ACF and cancer samples (Figure
2-8D); however, a greater number of AP-1 sites were affected in cancer samples than in ACF. Furthermore,
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Figure 2-7. Volcano plots depicting DMRs in colon cancers and ACF grouped by genomic region. DMRs
identified in ACF and colon tumors were segregated according to genomic location, and the methylation
changes in gene bodies (GBs), intergenic regions, and promoter regions were examined; DMRs are
depicted as blue dots. (A) Gene body-associated DMRs in ACF and colon tumors. In ACF, of the 349 Gene
body-associated 136 (39%) were hypomethylated while 213 (61%) were hypermethylated, indicating a
net increase in methylation. The opposite pattern was observed in colon tumors; of the 8,849 Gene bodyassociated DMRs in colon tumors, 6,591 (74%) were hypomethylated while only 2,258 (26%) were
hypermethylated. (B) Intergenic DMRs in ACF and colon tumors. Of the 297 intergenic DMRs identified in
ACF 129 (43%) were hypomethylated, while 168 (57%) were hypermethylated, again indicating a net
increase in methylation. Again, the opposite pattern was observed in intergenic DMRs detected in colon
tumors; 10,401 (85%) intergenic DMRs were hypomethylated while only 1,769 (15%) were
hypermethylated. Together, these observations indicate that non-promoter DMRs undergo a switch in
methylation status during cancer progression. (C) Promoter-associated DMRs in ACF and Stage II colon
tumors. Of 165 promoter-associated DMRs identified in ACF, only 9 (5%) were hypomethylated, while 156
(95%) were hypermethylated. The same pattern was observed in promoter-associated DMRs identified in
colon tumors, 758 (28%) were hypomethylated while 1,968 (72%) were hypermethylated. Thus, in both
ACF and Stage II colon tumors, promoter-associated DMRs exhibit a net increase in methylation.
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Figure 2-7
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Figure 2-8. Enrichment of AP-1 binding motifs in intergenic DMRs. DMRs from ACF and cancers were
subjected to Hypergeometric Optimization of Motif EnRichment (HOMER) analysis to determine whether
they were enriched for known regulatory elements. (A) In ACF, intergenic DMRs were found to be heavily
enriched for sequences corresponding to the binding motifs of AP-1 transcription factor family members,
indicated with an asterisk. No motifs were significantly enriched in gene body or promoter DMRs in ACF.
(B) Density plot of motif scores for AP-1 family binding motifs generated via bootstrapping analysis.
Asterisks indicate the actual enrichment score for each motif observed in intergenic ACF DMRs. (C) 103
motifs were found to be enriched in intergenic DMRs in cancers, including the 6 motifs previously
identified as enriched in ACF intergenic DMRs, indicating that the enrichment of intergenic DMRs for AP1 binding motifs is a cancer-associated phenomenon. (D) Change in methylation of DMRs enriched for AP1 binding motifs in ACF and cancer. In both sample types, the DMRs containing AP-1 binding motifs were
significantly hypomethylated compared to their respective matched normal samples. This pattern was
particularly prominent in cancer samples, where 95% of AP-1 enriched DMRs were hypomethylated.
Furthermore, a greater number of AP-1 sites were affected in cancer than in ACF. (E) Average change in
percent methylation of DMRs enriched for AP-1 family motifs. Intergenic DMRs containing AP-1 binding
motifs exhibited a ~15% reduction in methylation in ACF and a ~25% reduction in cancer. Bars represent
average change in methylation of all DMRs containing the indicated motif. Error bars represent SEM.
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Figure 2-8
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as shown in Figure 2-8E, the average degree of hypomethylation at AP-1 motif-associated DMRs was
greater in cancers than in ACF.

Aberrant DNA methylation is associated with altered gene expression in colon cancers
Promoter methylation is an important mechanism for regulating gene expression (29). To assess
the functional consequences of aberrant promoter methylation, genome-wide RNA-Seq analysis was
performed on CRC and ACF samples. Scatter-plots depicting the correlation between promoter
methylation and gene expression are shown in Figure 2-9. In CRCs, promoter methylation was negatively
correlated with gene expression (Pearson’s correlation coefficient = -0.55) (Figure 2-9A), consistent with
the transcriptional silencing commonly found in advanced neoplasia (29). However, when ACF were
subjected to a similar analysis, there was no correlation observed between promoter methylation status
and changes in gene expression (Pearson’s correlation coefficient = -0.07) (Figure 2-9B).
This lack of correlation between promoter methylation and gene expression in ACF may be related
to the magnitude of methylation changes. To address this possibility, 12 genes with promoter
hypermethylation in both CRC and ACF, but reduced expression in CRC only, were selected for further
analysis of their promoter methylation statuses. As shown in Figure 2-10A, the expression of GSG1L, DPP6,
NEFL, GRIN2A, SORCS1, NPTX1, SFRP1, ST8SIA5, ADCYAP1R1, SNAP25 and GABRB3 were each significantly
reduced by at least 3-fold in Stage III-IV cancers, but had no significant change in expression in ACF. These
genes showed an average increase in promoter methylation of ~40% in CRCs, but an increase of only ~20%
in ACF (Figure 2-10B), suggesting that the extent of promoter methylation in early neoplasia is insufficient
to alter gene expression.
Overexpression of EZH2, the catalytic subunit of PRC2, has been identified in CRC and is frequently
associated with a poor prognosis (153). To determine whether the enrichment of ACF DMRs for PRC2
targets may be due to the overexpression of components of the PRC2 complex, we interrogated our RNA-
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Figure 2-9. Promoter methylation is correlated with gene expression in CRCs but not ACF. (A) Scatterplot depicting the correlation between changes in promoter methylation and gene expression in CRCs
(Pearson’s correlation coefficient = -0.55), indicating increased promoter methylation associated with
gene silencing. (B) Scatter-plot depicting the lack of correlation between changes in promoter methylation
and gene expression in ACF (Pearson’s correlation coefficient = -0.07).
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Figure 2-10. Relationship between DNA methylation and expression for selected genes. (A) Selected
genes with promoter DMRs identified in both cancer and ACF. GSG1L, DPP6, NEFL, GRIN2A, SORCS1,
NPTX1, SFRP1, ST8SIA5, ADCYAP1R1, SNAP25, and GABRB3 were significantly downregulated in cancer
samples (at least 3-fold reduction in expression), but not significantly altered in ACF. (B) These same genes
exhibit promoter hypermethylation in both cancer and ACF, but the degree of increased methylation is
greater in cancer (~40% increase) than in ACF (~20% increase). Bars represent average percentage change
in methylation of promoter DMRs for indicated genes across samples. Error bars represent 95%
confidence interval and SEM in (A) and (B), respectively.
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Seq data for changes in expression of the Polycomb genes EZH2, SUZ12, and EED. As shown in Figure 211A, EZH2 was overexpressed in Stage III-IV CRCs (1.55-fold increase, p=0.03), but not in ACF (Figure 211B). We also interrogated the RNA-Seq dataset for the expression levels of the DNA methyltransferases
(DNMTs), a group of genes (DNMT1, DNMT3A and DNMT3B) that are often up-regulated in CRC (154). As
shown in Figure 2-11A&B, DNMT1 and DNMT3B are overexpressed in cancer samples, but not in ACF.
Taken together, these results suggest that while overexpression of EZH2, DNMT1 and DNMT3B may
promote hypermethylation and cancer progression, their overexpression is not required for the
establishment of early colonic neoplasia. Alternatively, higher expression of DNMT1, DNMT3B and EZH2
may accompany increased cell proliferation in CRC but may not be causative for the DNA methylation
changes.

2.4 Discussion
The disruption of DNA methylation patterns has been shown to play an important role in the
pathogenesis of CRC (30). However, the epigenomic landscape at the earliest stages of colonic neoplasia
has not been clearly defined. Several studies have demonstrated methylation defects within a limited set
of genes in ACF and the normal colonic mucosa from patients with CRC (24,25,47,48). However, a
systematic genome-wide investigation of DNA methylation changes occurring in early human colonic
neoplasia has not yet been reported. In the present study, we have applied a highly sensitive genomewide approach by combining LCM with RRBS to compare DNA methylation changes present in early
colonic neoplasia with the extensive modifications found in advanced CRC.
As expected, the majority of DMRs identified in Stage III-IV cancers were hypomethylated. This
global loss of DNA methylation was particularly common within intergenic regions, in which ~85% of DMRs
were hypomethylated. These findings are consistent with previous reports of genome-wide
hypomethylation in a number of different human cancers (26,155). DNA hypomethylation also occurs in
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Figure 2-11. Expression of PRC2 components and DNA methyltransferases in cancer and ACF samples.
(A) Significant overexpression of the PRC2 components EZH2 (1.55-fold, P<0.05), SUZ12 (1.12-fold, P<0.05)
and EED (1.1-fold, P<0.05) were detected in cancer samples. Furthermore, overexpression of the DNA
methyltransferase enzymes DNMT1 (1.2-fold, P<0,05) and DNMT3B (1.45-fold, P<0.05) were detected in
cancers. (B) Despite similarities in the patterns of aberrant methylation in cancer and ACF, including the
enrichment of promoter DMRs for PRC2-target genes in ACF, no change in the expression of any PRC2
component or DNMT enzyme was detected in ACF samples.
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low-grade adenomas (155,156), indicating that this epigenetic alteration precedes the development of
more advanced malignancies. However, our present study has uncovered an unexpected finding; the
majority of DMRs (across all genomic locations) in ACF samples are hypermethylated, indicating a global
gain of DNA methylation at the earliest stages of tumor initiation. Since the majority of ACF are selflimiting and unlikely to progress to malignancy (93), genome-wide hypermethylation may in fact provide
a mechanism for restricting ACF progression, in part by reducing the likelihood of genomic instability
associated with DNA hypomethylation (27).
Promoter DMRs in both CRC and ACF were enriched in genes known to be targeted by PRC2 in
embryonic stem cells (ESCs). PRC2 is a histone-modifying complex expressed in ESCs that plays an
important role in maintaining ‘stemness' (150) by repressing genes required for differentiation via the
methylation of histone H3K27 (157). Since many genes targeted by PRC2 in human ESCs become
hypermethylated in CRC and other cancers (158,159), it is thought that PRC2 occupancy and/or histone
methylation

will

increase

the

susceptibility

of

genes

to

aberrant

hypermethylation (160,161). Widschwendter et al. (159) hypothesized that cancer-associated promoter
hypermethylation of PRC2 targets originates in stem cells during the earliest stages of carcinogenesis, and
predisposes these cells to neoplastic transformation by “locking in” a stem cell phenotype. Our data
support the timing of this hypothesis by demonstrating that hypermethylation of PRC2 targets occurs as
early as the ACF stage. While H3K27 methylation of PRC2 targets was originally thought to be restricted
to ESCs, Rada-Iglesias et al. (162) and Hahn et al. (163) showed that this modification is also found in
normal adult colonic epithelial cells. Together, these observations suggest that DNA hypermethylation in
ACF is directed by the Polycomb complex, or its associated histone marks that are present in normal cells
prior to early neoplastic initiation.
In addition, the present study has uncovered extensive promoter and gene body
hypermethylation of homeobox genes in both cancers and ACF, many of which belong to the HOX
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family. The expression of homeobox genes, which is regulated to a large extent by epigenetic
modifications (164,165), contributes to the maintenance of cellular identity and adult tissue morphology
(166). Aberrant hypermethylation of homeobox-containing genes has been described in breast and lung
cancers, and several HOX genes (HOXA7, HOXA9, and HOXB13) are reportedly hypermethylated in CRC
(158,167,168). However, the large number of differentially methylated homeobox genes identified in our
panel of primary Stage III-IV cancers (Figure 2-6) is an unexpected result. A subset of homeobox genes
was also hypermethylated in ACF, suggesting that this epigenetic change is an early event in colonic
neoplasia. CpG islands associated with homeobox genes are commonly hypermethylated in early stage
ductal carcinomas (DCIS) and early-stage lung carcinomas (158,168), suggesting that this change is an
early event in other tissues as well. Together, these results suggest that dysregulation of homeobox genes
via hypermethylation occurs more extensively in CRC than previously thought, and that this epigenetic
aberration is established in early neoplasia.
Finally, our results indicate that aberrant DNA methylation commonly occurs within nontranscribed, intergenic regions in both ACF and CRCs. Upon further analysis, we have found that intergenic
DMRs are enriched for transcription factor binding sites, especially those corresponding to members of
the AP-1 transcription factor family. AP-1 is a nuclear transcription factor that controls many critical
cellular functions, including proliferation, differentiation and apoptosis (169). AP-1 also plays an important
role in oncogenesis; activating mutations in the KRAS gene are thought to promote tumor development
by increasing AP-1 activity, with concurrent up-regulation of proliferative and anti-apoptotic genes (170).
Notably, all of the ACF and CRC samples examined in this study contained mutant KRAS. Recent evidence
indicates that transcriptional activation by AP-1 is controlled, in part, by DNA methylation (171). As shown
by Park et al. (171), the DNA binding activity of AP-1 is significantly reduced when CpGs in close proximity
to its DNA binding motif are methylated. A genome-wide methylation study of a single KRAS-mutant stage
III colon adenocarcinoma by Berman et al. (172) suggested that epigenetic regulation of AP-1 is disrupted
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in cancer by demonstrating that genomic regions with cancer-specific hypomethylation are significantly
enriched for AP-1 binding motifs. Our study has confirmed this observation in a larger panel consisting of
10 KRAS-mutant colon cancers, substantiating a role for hypomethylation of AP-1 sequences in CRC.
Furthermore, our data extend this hypothesis by demonstrating that a small number of AP-1 sites are
hypomethylated in ACF, suggesting that this epigenetic phenomenon begins early in the neoplastic
process. However, the number of affected AP-1 sites, and the average degree of hypomethylation at these
sites, was significantly greater in cancer samples than in ACF. These observations suggest that the
expansion of AP-1 site hypomethylation may promote neoplastic progression.
In summary, the present study demonstrates that cancer-associated DNA methylation changes
are more abundant in ACF than previously thought. These changes frequently affect genes involved in
cellular identity and differentiation, suggesting that disrupted regulation of cell fate determination may
contribute to the establishment of early colonic neoplasia. Methylation of these genes, including those
targeted by PRC2 or containing homeobox sequences, may be useful targets for novel chemopreventive
interventions. Furthermore, the present study identifies epigenetic changes specifically associated with
advanced neoplasia, including a switch in the global methylation status of non-promoter regions, which
may serve as useful biomarkers for cancer risk. Our results provide new insights into the role of DNA
methylation in the development of early colonic neoplasia, and provide target candidates for the use of
epigenetic profiling in CRC detection and prevention.
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Chapter 3: Dietary methyl donor deficiency suppresses intestinal adenoma development
3.1 Introduction
Many epidemiological studies and follow-up meta-analyses suggest that folate deficiency
increases the risk of developing colorectal cancer (CRC) (173–176). Consistent with this observation,
several small cohort and case-control studies have suggested that folate has a small protective effect
against CRC (177), although a more recent meta-analysis of 13 supplementation trials comprised of 50,000
individuals found no significant effect of folate on cancer incidence in the general population (115).
However, data from several recent clinical trials suggest that folate supplementation may actually increase
cancer risk in certain high-risk subpopulations (116,117). These findings are particularly troubling when
considered within the context of the USDA-mandated folate supplementation program that requires
cereals, flour and other grain products in the US to be fortified with folic acid. This program was initiated
to reduce the incidence of neural tube birth defects (NTDs) in newborns, and although highly successful
(178), it has had the unintended consequence of significantly raising blood folate levels within the general
population (179).
Subsequent studies of folate intake and disease risk have raised concern about the effects of this
widespread folate fortification on populations at low risk for NTDs, but high risk of cancer. A randomized,
placebo-controlled clinical trial by Cole and Baron (118) found that men with a personal history of
colorectal adenoma who received 1 mg/d supplemental folic acid were more likely to present with an
advanced colonic lesion at a 5-year follow-up examination. This finding may be of particular concern for
individuals with hereditary CRC syndromes, such as familial adenomatous polyposis (FAP), who develop
multiple neoplastic foci at a young age (180) and thus may be more susceptible to the potential cancerpromoting effects of folic acid supplementation. In addition, the prevalence of colorectal polyps in
individuals over the age of 50 is estimated to be as high as 45% (181–183); these individuals, who are
unlikely to become pregnant and are therefore not concerned with NTDs, could in fact be harmed by folic
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acid supplementation. An analysis of folate consumption before and after the implementation of
mandatory fortification revealed that men and women over the age of 50 experienced the largest increase
in folic acid intake (184).
Folate is a key component of folate one-carbon metabolism (FOCM). In addition to folate and its
derivatives, the nutrients choline, methionine and vitamin B12 are also fundamental components of this
metabolic pathway; these nutrients are collectively referred to as ‘methyl donors’. Through FOCM, onecarbon moieties are utilized in nucleotide biosynthesis and methylation reactions, although these
processes are regulated by two distinct arms of the FOCM pathway (185). In one arm, nucleotide
biosynthesis is directly dependent upon the availability of folate and its derivatives. In the other arm,
protein and DNA methylation reactions are dependent upon the generation of S-adenosylmethionine
from choline, homocysteine and methionine. Vitamin B12 serves as a link between these two key arms of
the pathway by transferring methyl groups from the folate cycle to the methionine cycle (186).
The fundamental cellular processes controlled by FOCM illustrate the importance of maintaining
methyl donor homeostasis; inhibition of FOCM flux can have severe consequences for DNA stability, gene
expression and cell survival. Under normal conditions, it is important for cells to have an adequate supply
of methyl donor nutrients. However, rapidly replicating cancer cells have an increased demand for folate,
making FOCM an ideal target for anti-cancer interventions (187). Anti-folates, a class of chemotherapeutic
agents that disrupt key steps in FOCM, have had a long history of success in the clinic (188). Less is known,
however, about whether dietary manipulation of methyl donor nutrients can be used to prevent
carcinogenesis.
We recently reported the effects of combined dietary depletion of folate, methionine, choline and
vitamin B12 on tumor development in ApcMin/+ mice, a model of Wnt-driven intestinal cancer (122,189).
ApcMin/+ mice, maintained on a methyl donor deficient (MDD) diet beginning at 5 weeks of age, were
significantly protected against intestinal tumorigenesis (~96% reduction in tumor number; P<0.01). This
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reduction in tumor burden was associated with a broad decline in immune cell populations and decreased
expression of pro-inflammatory cytokines (122). In the present study, the effects of dietary MDD are
examined in greater detail in the Apc14/+mouse, a mouse model with an Apc truncation mutation more
typical of that found in human cancers and a higher prevalence of colon tumor development (190). An 11week period of methyl donor restriction started prior to tumor initiation is shown to afford long-lasting
tumor protection, even when mice are returned to dietary repletion. Protection is accompanied by
significant morphological changes to the intestinal crypt architecture, including altered cell turnover and
a reduction in the number of cryptal Dclk1-positive cells. Finally, the undesirable effects associated with
methyl donor restriction are shown to be transient and readily reversible following methyl donor
repletion. Taken together, these results indicate that temporary dietary methyl donor restriction in
adenoma-prone mice can induce persistent changes to the intestinal epithelium and provide long-lasting
tumor protection. These data also suggest that transient reductions in dietary methyl donor consumption
should be considered when studying the impact of folate on colon cancer risk in humans.

3.2 Materials and Methods
Animal treatment
ApcΔ14/+ mice on a C57BL/6 background were generated and kindly provided by Dr. Christine
Perret as previously described (190). All mice were maintained in a temperature-controlled, light-cycled
room and allowed free access to drinking water. Animal experiments were conducted with approval from
the Institutional Animal Care and Use Committee (UConn Health). Genotyping of Apc was performed by
PCR using DNA from mouse tail biopsies. Dietary studies used two amino-acid defined experimental diets:
the Methyl Donor Sufficient (MDS; TD.99366, Harlan Laboratories, Madison WI) diet and the Methyl
Donor Deficient (MDD; TD.00605) diet, which was identical to the MDS diet except for the depletion of
folate, choline, methionine and vitamin B12, and the addition of homocysteine. Diet compositions are
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detailed in Table 3-1. Apc14/+ mice were randomized at 4 weeks of age and placed into four experimental
groups; each group was placed on a specific dietary regimen for 18 weeks, as depicted in Figure 3-1. Group
I (MDS, n=28) mice were fed the MDS diet ad libitum for the entire 18-week period. Group II (MDD, n=19)
mice were fed the MDD diet ad libitum for 18 weeks. Group III (MDS-PF, n=27) mice were pair-fed the
MDS diet in an amount equivalent to levels consumed by Group II mice. Finally, mice in Group IV
(MDD:MDS, n=28) were placed on the MDD diet for 11 weeks, and then switched to the MDS diet for the
remaining 7 weeks. All mice were sacrificed at 22 weeks of age. Mice were examined weekly for changes
in body weight, rectal prolapse, or bleeding indicating intestinal obstruction or anemia associated with
tumors. Individual body weights and average food consumption were recorded weekly.

Tissue processing and analysis of tumor burden
Upon sacrifice, the entire small intestine, colon, liver, spleen and kidneys were harvested. The
small intestine and colon were flushed with ice-cold PBS and opened longitudinally. Specimens were fixed
flat in 10% neutral buffered formalin solution and stored in 70% ethanol. Tissues were stained with 0.2%
methylene blue and the numbers, size and location of tumors were scored under a dissecting microscope.
Size was measured as tumor diameter at its widest point.

Histological and Morphometric Analyses
After tumor quantification, tissues were processed and paraffin-embedded for subsequent
histological analyses. Paraffin-embedded tissues were sectioned onto glass slides at a thickness of 5-µm
and stained with hematoxylin and eosin (H&E). Liver and kidneys were also stained with Masson’s
trichrome stain to visualize collagen deposition. All tissues were examined for histological abnormalities
using an Olympus BX60 light microscope. H&E-stained small intestine and colon tissue sections were used
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Table 3-1. Nutritional composition of MDD and MDS diets.
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Figure 3-1. Dietary methyl donor deficiency study design. At 4 weeks of age, a total of 102 mice were
randomized and placed into 4 experimental groups. Group 1 (MDS ad lib., n=28) received MDS diet ad
libitum, group 2 (MDS pair fed, n=27) received MDS diet pair fed with group 3 (MDD, n=19) which received
the MDD diet; all mice in groups 1, 2, and 3 received their respective diets for 18 weeks, starting at 4
weeks of age. In addition, mice in group 4 (MDD:MDS, n=28) were placed on the MDD diet for 11 weeks,
starting at 4 weeks of age, before being transferred to the MDS diet for an additional 7 weeks. All mice
were sacrificed at 22 weeks of age.
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for morphometric analysis. Crypt length was measured using ImageJ image processing software calibrated
using an ocular micrometer. Four 20x regions per animal (n=4/group) were randomly selected in the ileum
and colon, and a minimum of 5 crypts was measured per region. Data are reported as the mean crypt
length in micrometers. Crypt branching index (CBI) was calculated by averaging the total number of
branched crypts in 3 H&E sections per animal (n=4/group).

Immunohistochemistry and Quantification of Immunostaining
Immunostaining was performed as previously described (191). Sections were subjected to sodium
citrate antigen retrieval; for cleaved caspase-3 antigen retrieval 0.05% Tween-20 was added to the sodium
citrate buffer. Sections were incubated overnight at 4C with anti–Ki-67 (1:600; Cell Signaling Technology,
Inc.), anti–phospho-Histone H3 (PHH3; 1:200; Cell Signaling Technology, Inc.), anti-cleaved caspase-3
(CC3; 1:400; Cell Signaling Technology, Inc.), or anti-DCAMKL1 (Dclk1; 1:50; Abcam). All sections were then
incubated with SignalStain Boost IHC Detection Reagent (Mouse, HRP, Cell Signaling Technology, Inc.). For
quantification of Ki-67 staining in normal tissue, 30 crypts with complete longitudinal sections were
randomly selected from 4 mice per group. Ki-67 index was calculated as the average percent Ki-67–
positive cells per crypt. Ki-67 staining in tumors was quantified in a minimum of 2,000 cells from five fields
per mouse (40x). For quantification of PHH3 and Dclk1 staining in normal tissue, 150 crypts with complete
longitudinal sections were chosen at random from 4 mice per group. The total number of positive-stained
cells per crypt were counted, averaged, and reported as the percent positive cells per crypt. For tumor
tissue, a minimum of ten fields (40x) was selected and PHH3-index was calculated as the average number
of PHH3+ cells per field. CC3 staining was quantified in normal and tumor tissue by averaging the total
number of CC3-positive cells in ten fields (40x).
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Statistical Analysis
Comparisons of small intestine and colon tumor multiplicity were made using the Kruskal-Wallis
test with Dunn’s Multiple Comparisons post-test. Comparisons of small intestine and colon crypt length,
and crypt branching indices, were made using one-way ANOVA with Bonferroni’s post-test. Individual
comparisons of tumor size, Ki-67, PHH3, CC3 and Dclk1 immunostaining were made using Fisher’s exact
test, or one-way ANOVA with Bonferroni’s post-test when appropriate. For all analyses, a P-value < 0.05
was considered to be statistically significant.

3.3 Results
Methyl donor deficiency induces a sustained reduction in intestinal tumor formation
Our recent study in ApcMin/+ mice showed dramatic tumor protection by restricting the
consumption of diet-derived methyl donors (122). To extend these results to a second Apc-dependent
mouse tumor model, the following study was conducted in ApcΔ14/+ mice, in which tumor formation is
driven by the deletion of Apc exon 14 (190). ApcΔ14/+ mice were maintained on four experimental diets, as
depicted in Figure 3-1. As shown in Figure 3-2A, tumor multiplicity was evaluated in the small intestine.
Methyl donor restriction significantly reduced the total number of polyps by 78% (70.2 ± 24.6 vs. 15.4 ±
14.7 in MDS and MDD, respectively; P<0.01). A group of MDS mice were also pair-fed to the MDD mice to
match their reduced food consumption and lower calorie intake (MDS-PF). Pair-fed mice showed an
intermediate reduction (37%; P<0.05) in intestinal tumor multiplicity (Figure 3-2A), consistent with our
earlier study (122), indicating that reduced calorie consumption cannot fully account for the protection
afforded by the MDD diet.
To determine whether tumor protection persists beyond the period of active methyl donor
restriction, an additional group of mice was methyl donor depleted for an initial 11 weeks, beginning at 4
weeks of age, and then returned to a methyl donor replete diet for an additional 7 weeks (MDD:MDS). As
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shown in Figure 3-2A, the number of small intestinal tumors was significantly reduced (68%, P<0.01) in
the MDD:MDS mice compared to MDS mice (22.2 ± 18.8 versus 70.2 ± 24.6, respectively). There was also
no significant difference in the number of small intestinal tumors between MDD:MDS and MDD mice,
indicating that tumor protection is maintained even after dietary repletion of methyl donors. There was
a downward shift in the size distribution of tumors in the MDD and MDS-PF groups, with the most
pronounced shift present in mice maintained on the MDD diet throughout the entire 18-week study
(Figure 3-2B). In the colon, methyl donor restriction significantly reduced the total number of tumors by
50% (3.0 ± 2.1 versus 1.5 ± 1.9 in MDS and MDD, respectively; P<0.01), an effect that was not observed in
the pair-fed mice. MDD:MDS displayed a moderate (23%), but non-significant (P=0.19) reduction in
tumors (Figure 3-2C). The size distribution of colon tumors was shifted downward in the MDD-fed mice,
but this downward shift was not present in the MDD:MDS group (Figure 3-2D).

Methyl donor deficiency alters crypt morphology and cell turnover
Interventions that reduce intestinal cancer risk are frequently accompanied by reduced crypt
length, decreased cell proliferation, decreased crypt branching and increased apoptosis (192). The MDD
diet produced each of these changes, and these alterations persisted even after dietary methyl donors
were replenished. As shown in Figure 3-3A, small intestinal crypt length was reduced in both the MDD
(26%; P<0.01) and MDS pair-fed mice (15%; P<0.01) compared to MDS controls. This effect was also
observed in the MDD:MDS mice (16%; P<0.01), indicating that compacted crypt morphology is maintained
after methyl donor repletion. In the colon, average crypt lengths were significantly reduced in both the
MDD (20%; P<0.01) and MDD:MDS mice (6%; P<0.05) (Figure 3-3B).
Intestinal epithelial growth can be controlled via crypt fission (193). Furthermore, crypt fission
acts as a pathway for Apc-mutant crypts to clonally expand, thereby increasing the risk of tumor formation
(194). As shown by Fischer et al. (194), reduced crypt fission is associated with diminished tumor burden
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Figure 3-2. Intestinal tumor burden. (A) Total number of tumors per mouse in the small intestine. Caloric
restriction (MDS pair fed) causes a modest reduction (37 ± 4.2%, P<0.05) in tumor multiplicity, while MDD
causes a larger reduction (78 ± 5%, P<0.01). Note, there is no significant difference in tumor number in
the MDD and MDD:MDS groups, indicating that protection from tumor formation induced by 11 weeks of
MDD persists through at least 7 weeks of methyl donor repletion. (B) Distribution of small intestine tumor
sizes. Caloric restriction and MDD both cause a downward shift in the distribution of intestinal tumor sizes.
(C) Total number of tumors per mouse in the colon. MDD causes a reduction (51 ± 14%, P<0.01) in the
average number of colon tumors; however, caloric restriction does not have an effect on colon tumor
multiplicity. (D) Distribution of colon tumor sizes. MDD causes a downward shift in colonic tumor size
distribution; however, caloric restriction does not. Thus, even when tumors are able to form, their growth
is inhibited by MDD. Error bars indicate means ± SEM. Statistically significant differences (P<0.05)
between groups, measured by the Kruskal-Wallis test with Dunn’s Multiple Comparisons post-test, are
indicated within dot plots by differences in the letter placed above each group.
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Figure 3-3. Intestinal and colonic crypt length and fission rates. (A) Representative images of normal
small intestine crypts used for morphometric analysis, with quantification. MDD was associated with an
approximately 25% reduction (P<0.01) in the average length of normal small intestine crypts. Average
crypt length is also reduced in MDD:MDS mice (16% reduction, P<0.01), suggesting long-term changes to
crypt homeostasis. (B) Representative images of normal colon crypts used for morphometric analysis, with
quantification. MDD was associated with an approximately 20% reduction (P<0.01) in average crypt
length. (C) Small intestine crypt branching index (CBI) was reduced in the MDD mice (73%, P<0.01),
indicating a reduced rate of crypt fission under conditions of dietary methyl donor restriction. Error bars
indicate means ± SEM. Statistically significant differences (P<0.05) between groups, measured by ANOVA
with Bonferroni’s post-test, are indicated within bar graphs by differences in the letter placed above each
group. Scale bars, 80 and 120 µm.
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in Apc-mutant mice. To determine whether MDD diet decreases crypt fission, the intestinal crypt
branching index (CBI), a measure of the rate of crypt fission (195), was assessed. A representative image
of a small intestine crypt from the MDS mice undergoing crypt fission is shown in Figure 3-3C. Although
already a rare event in normal mucosa (193), the CBI was further reduced in both the MDD (73%; P<0.01)
and MDS-PF (56%; P<0.01) groups (1.25 ± 0.5 and 2 ± 0.14 versus 4.6 ± 0.4 branched crypts per section,
respectively). The CBI in MDD:MDS mice remained significantly reduced (71%; P<0.01) relative to MDS
controls (1.3 ± 0.3 versus 4.6 ± 0.4 branched crypts per section), indicating that impaired crypt fission
continues after methyl donor repletion. Similar changes did not occur in the colon (data not shown).
Diet can also influence intestinal cancer development through the modulation of cell proliferation
and apoptosis (196). As shown in Figure 3-4A, Ki-67 staining was significantly reduced in both MDD (12%,
P<0.01) and MDD:MDS (6%, P<0.01) mice. In addition, Ki-67+ cell numbers in extant tumors were also
reduced in MDD (24%, P<0.01) and MDD:MDS mice (6%, P<0.01) (Figure 3-4B). Apoptotic cells were
identified by immunostaining for CC3. As shown in Figure 3-5A, CC3+ cells were intermittently present
within the upper portion of small intestinal villi, tending to cluster towards the villus tip and rarely found
within the crypt compartment. MDD significantly increased (4.9-fold; P<0.01) the average number of CC3+
cells per field (Figure 3-5A). However, increased numbers of apoptotic cells did not persist upon methyl
donor repletion (MDD:MDS, Figure 3-5A). Similar patterns of apoptosis were observed in intestinal
tumors, regardless of size or location (Figure 3-5B). There were no differences observed in CC3 staining in
colon tumors or normal colonic mucosa of mice from each of the experimental groups (data not
shown). An increased rate of apoptosis is therefore unlikely to contribute to adenoma risk reduction in
the MDD:MDS mice.
The effects of methyl donor status on mitosis were also evaluated within the intestinal mucosa.
As shown in Figure 3-6A, methyl donor restriction (MDD) significantly reduced the frequency of PHH3 +
cells per crypt by 53% (P<0.01). Reduced numbers of mitotic cells were also present within the small
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Figure 3-4. Immunohistochemical staining of Ki-67 in normal crypts and tumors of the small intestine.
(A) Representative images of Ki-67 staining in normal crypts, with quantification. MDD caused a small
reduction (12%, P<0.01) in the average percentage of Ki-67+ cells per crypt. MDD:MDS mice exhibited a
small (6%, P<0.01), but significant, reduction in the average percentage of Ki-67+ cells per crypt, possibly
indicating that MDD-induced inhibition of proliferation persists during methyl donor repletion in normal
crypts. (B) Representative images of Ki-67 staining in tumors, with quantification. Tumor proliferative
index was determined by calculating the average percentage of Ki-67+ cells in 5 40x fields per mouse
(minimum 2000 cells counted). MDD induced a modest reduction (17%, P<0.01) in proliferative index in
tumors of the small intestine. There was no reduction in proliferative index in tumors from MDD:MDS
mice, indicating that MDD-induced reductions in proliferation are reversed by repletion with MDS diet.
Bars indicate means ± SEM. Statistically significant differences (P<0.05) between groups, measured by
ANOVA with Bonferroni’s post-test, are indicated within bar graphs by differences in the letter placed
above each group. Scale bars, 80 and 200 µm.
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Figure 3-5. Immunohistochemical staining of Cleaved Caspase-3 (CC3) in normal crypts and tumors of
the small intestine. (A) CC3 staining in normal tissue, with quantification.

Apoptotic index was

determined by calculating the average number of apoptotic cells in 10 40x fields of view per mouse. MDD
caused an approximately 5-fold increase (P<0.01) in apoptotic index in normal tissue. Apoptotic cells were
primarily located in the villi and tended to cluster towards the villous tip. (B) Representative images of
CC3 staining in tumors of the small intestine, with quantification. Caloric restriction (MDS pair fed) and
MDD caused 2-fold (P<0.01) and 3.1-fold (P<0.01) increases in apoptotic index, respectively. Apoptotic
cells were scattered throughout the tumor with no obvious localization. Bars indicate means ± SEM.
Statistically significant differences (P<0.05) between groups, measured by ANOVA with Bonferroni’s posttest, are indicated within bar graphs by differences in the letter placed above each group. Scale bars, 200
and 120 µm.
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Figure 3-6. Immunohistochemical staining of phospho-Histone H3 (PHH3) in normal crypts and tumors
of the small intestine. (A) Representative images of PHH3 staining in normal small intestine, with
quantification. MDD induced a large reduction in the average number of PHH3+ cells per crypt in the small
intestine on (53%, P<0.01), suggesting an inhibition of mitosis. The average number of PHH3+ cells per
crypt was also reduced in the MDD:MDS mice (35% reduction, P<0.01), suggesting that mitotic inhibition
in normal crypts persists through at least 7 weeks of methyl donor repletion. (B) Representative images
of PHH3 staining in tumors, with quantification. Tumor mitotic index was calculated by averaging the
number of PHH3+ cells in 10 40x microscope fields; MDD caused a large reduction (81%, P<0.01) in tumor
mitotic index. Mitotic index was also reduced in tumors from MDDMDS mice (31%, P<0.05), indicating
that mitotic inhibition in tumors persists, to a lesser degree, at least 7 weeks beyond methyl donor
repletion. (C) Representative images of PHH3 staining in normal colon crypts, with quantification. MDD
induced a large reduction in the average number of PHH3+ cells per crypt in the colon (48%, P<0.01,
respectively), suggesting an inhibition of mitosis. Bars indicate means ± SEM. Statistically significant
differences (P<0.05) between groups, measured by ANOVA with Bonferroni’s post-test, are indicated
within bar graphs by differences in the letter placed above each group. Scale bars, 80 and 120 µm.
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Figure 3-6
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intestines of the MDD:MDS mice (35%; P<0.01), indicating persistent changes to crypt cell
homeostasis. MDD also reduced the fraction of cells undergoing mitosis in small intestinal tumors (Figure
3-6B). In the colon, methyl donor restriction caused a significant reduction in the numbers of PHH3+ cells
in both the MDD group (48%, P<0.01) and the MDD:MDS group (25%; P<0.05) (Fig. 3-6C).

Methyl donor restriction causes persistent depletion of Dclk1+ intestinal stem cells
Immunohistology was used to examine cells expressing Doublecortin-like kinase 1 (Dclk1), a
putative stem cell marker (197), in crypts of the small intestine and colon. Dclk1+ cells contribute to the
regulation of crypt homeostasis, as demonstrated by the fact that their ablation leads to a significant
reduction in Ki-67+ crypt epithelial cells (198). Importantly, it has also been suggested that Dclk1+ cells can
act as the initiating cell type for tumors in the ApcMin/+ mouse (198). Consistent with previous reports
(197), Dclk1+ cells were observed scattered throughout the intestinal and colonic epithelium, but were
concentrated in the lower portion of the crypt (Figure 3-7A). However, both methyl donor restriction and
pair-feeding significantly reduced the number of Dclk1+ cells within small intestinal crypts compared to
Dclk1 staining in MDS controls (62%, P<0.01 and 36%, P<0.01, respectively, (Figure 3-7A). The frequency
of Dclk1+ cells remained suppressed in the MDD:MDS mice (32%, P<0.01), indicating a persistent depletion
of this stem cell marker, even after methyl donor repletion (Figure 3-7A). A similar effect was observed in
the colon; Dclk1+ cells were reduced in both the MDD (41%; P<0.01), MDS-PF (26%; P<0.01) and MDD:MDS
mice (25%; P<0.01) (Figure 3-7B). Since Dclk1+ cells can serve as a cell type of origin for tumors formed in
Apc mutant mice, the reduction in Dclk1+ cell numbers associated with MDD may be related to the tumorprotective effects of the MDD diet.
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Figure 3-7. Immunohistochemical staining of Dclk1 in normal crypts and tumors of the small intestine.
(A) Dietary MDD is associated with a reduction in the average number of Dclk1+ cells per crypt is reduced
in the small intestine (62% reduction, P<0.01). Importantly, Dclk1+ cells are also reduced in the MDD:MDS
mice (32% reduction, P<0.01), suggesting that this reduction is long-lasting. (B) Dietary MDD is associated
with a reduction in the average number of DCLK1-positive cells per 40x field in tumors of the small
intestine (74% reduction, P<0.01). (C) Dietary MDD is also associated with a significant reduction in the
number of Dclk1+ cells in normal colonic crypts (41% reduction, P<0.01) in MDD mice. Dclk1 is a putative
marker for intestinal tumor stem cells, and so the reduction of Dclk1+ cell populations by dietary MDD may
underlie its protective effects. Error bars indicate means ± SEM. Statistically significant differences
(P<0.05) between groups, measured by ANOVA with Bonferroni’s post-test, are indicated within bar
graphs by differences in the letter placed above each group. Scale bars, 80 and 200 µm.
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Adverse effects of methyl donor deficiency are reversed by methyl donor repletion
The dietary restriction of methyl donors can result in a number of pathologies (199–
201). Consistent with our earlier study in ApcMin/+ mice, MDD interfered with normal weight gain. At 22
weeks of age, body weights were significantly lower (45%, P<0.01) in the MDD and MDS-PF mice
compared to the MDS mice (11.2 ± 2.1 g and 11.6 ± 1.38 g vs. 20.3 ± 3.3 g, respectively, P<0.01) (Figure 38). However, the inhibited body weight gain caused by 11 weeks of MDD was readily reversible upon
methyl donor repletion, with normal body weights achieved within two weeks (Figure 3-8). Histological
changes associated with MDD were also evaluated. As shown in Figure 3-9A, MDD caused significant
hepatic steatosis, evidenced by the presence of clear vacuoles formed by excessive fat
deposition (202). However, these fatty deposits were not present in the livers of MDD:MDS mice,
indicating that the steatosis was readily reversible upon methyl donor repletion. Spleens harvested from
mice maintained on the MDD diet showed evidence of depleted white pulp accompanied by a reduction
in the size and number of splenic follicles, indicating a reduction in B lymphocyte populations (Figure 39B). These findings are consistent with reports that folate deficiency inhibits lymphocytic proliferation
(200) and are consistent with our previous observations in ApcMin/+ mice (122). Changes to the white pulp,
however, were fully reversible in the MDD:MDS mice. Finally, hyperhomocysteinemia caused by choline
or folate deficiency has been shown to induce renal fibrosis, particularly around glomeruli (201). However,
using Masson’s Trichrome staining to visualize collagen deposition, there was no evidence of renal fibrosis
in any of the experimental groups (Figure 3-9C).

3.4 Discussion
This study expands upon our previous work (122) and demonstrates in a second Apc-mutant
mouse model the adenoma-suppressive properties of dietary methyl donor restriction. The study further
demonstrates that even a temporary period of dietary methyl donor restriction imparts long-lasting tumor
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Figure 3-8. Body weight changes in Apc14/+ mice. Body weights of mice in each experimental group were
recorded weekly throughout the study; each point represents average body weight ± SEM. At the end of
the study, mice in groups 2 (MDS pair fed) and 3 (MDD) were reduced by approximately 45%. Mice in
group 4 (MDD:MDS) initially failed to gain weight and at the time of transfer to MDS diet (15 weeks of
age) weighed approximately 33% less than group 1 (MDS ad lib.) mice. However, following methyl donor
repletion with the MDS diet, group 4 mice rapidly gained weight and had returned to a normal body
weight by the end of the study. Error bars indicate means ± SEM.
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Figure 3-9. Adverse effects of dietary MDD. (A) Representative images of liver H&E staining from the four
experimental groups. Mice maintained on MDD diet for 18 weeks develop hepatic steatosis, as evidenced
by the presence of vacuoles formed by fat accumulation. These vacuoles are not present in the liver of
MDD:MDS mice, indicating that hepatic steatosis is reversed after 7 weeks of methyl donor repletion. (B)
Representative images of spleen H&E staining; MDD mice show a loss of white pulp (stained purple) and
follicles, indicating a reduction in splenic lymphocyte populations. As before, spleens from MDD:MDS
mice do not show evidence of lymphocytic depletion, indicating that this effect of the MDD diet is
reversible by methyl donor repletion. (C) Chronic choline deficiency has been reported to cause renal
fibrosis, particularly around glomeruli. Using Masson’s Trichrome stain to visualize collagen deposition
(blue), we did not find evidence of renal fibrosis in MDD mice. Scale bars, 200 and 800 µm.
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protection to the intestine, an effect that persists for at least 7 weeks after mice have been returned to a
methyl donor sufficient diet. While some reports have suggested that folic acid may have
chemopreventive efficacy in the general population (203,204), data from recent studies suggest that high
levels of folic acid intake may increase the likelihood of cancer development in certain populations by
accelerating the progression of pre-existing lesions (118). The present study and our previous work (122)
support these observations and suggest that short-term reduced intake of folic acid, methionine, choline
and vitamin B12 may benefit those individuals at elevated risk of CRC. Furthermore, the sustained tumor
protection described in this report, which persists beyond the period of active methyl donor restriction,
implies that this dietary manipulation causes long-term changes to the intestinal mucosa that can impede
tumor initiation.
Evidence from several studies suggests that the benefits of methyl donor-based chemoprevention
strategies are heavily dependent upon the timing of administration (174). As shown by Song et al. (205),
Apc+/-Msh2-/- mice fed a folate-supplemented diet prior to the establishment of neoplastic foci benefit
from significantly reduced intestinal adenoma multiplicity; however, a folate-supplemented diet initiated
after the formation of neoplastic foci has the opposite effect. Furthermore, our previous work
demonstrates that the tumor protective effects of dietary MDD are abrogated when dietary
administration is delayed beyond 10 weeks of age in ApcMin/+ mice (122). Thus, it will be important for
future studies to examine how the timing of MDD with respect to age and neoplastic progression impacts
long-term protection.
The tumor protection afforded by methyl donor restriction is associated with alterations to
intestinal morphology and cell turnover, assessed by a morphometric analysis of cryptal structure, crypt
fission rates and analysis of cell turnover characteristics. Importantly, many of these alterations were
retained following methyl donor repletion. Specifically, MDD was associated with a reduction in crypt
length and crypt branching, suggesting altered intestinal growth and homeostasis. Crypt branching is a
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measure of the rate of crypt fission (195), a process that controls intestinal growth, in which crypts divide
longitudinally, initiated by stem cells located at the crypt base (193). Crypt fission has recently been
implicated in intestinal cancer progression, providing a mechanism for the occult expansion of mutant
crypts (194). As shown by Fischer et al. (206), mutant intestinal crypts in Apc-deficient mice clonally
expand via crypt fission, creating fields of normal-appearing mutant crypts that are poised for
tumorigenesis. A follow-up study by the same investigators demonstrated that reduced crypt fission is
associated with decreased tumor multiplicity in Pms2Cre/Cre;ApcCKO/CKO mice (194). Thus, our findings are
consistent with a role for MDD in reducing adenoma risk by limiting crypt fission. As crypt fission is
initiated by ISCs (193,195), this observation may reflect changes to the intestinal stem cell pool.
Tumor protection was also associated with altered crypt homeostasis, as evidenced by the
reduced proliferation of cells within the crypt epithelium. In a comprehensive review, Lipkin
(207) discussed the possibility that increased susceptibility to cancer may be related to the basal
proliferative rate within the normal colonic mucosa. Several studies have demonstrated an association
between increased proliferation of normal mucosa and the risk of developing cancer (207,208). In a casecontrol study by Mills et al. (209), samples of normal mucosa from individuals with FAP or sporadic CRC
were shown to have a markedly increased fraction of mitotic cells compared to healthy controls. These
findings suggest that elevated basal proliferation of normal gut mucosa may be an important early and
predisposing factor in cancer development. As reviewed by Tammariello and Milner (210), a large number
of dietary agents have been tested for their chemopreventive benefit in Apc mouse models; among the
most effective cancer prevention strategies are those agents that target cell proliferation rates within
morphologically normal, but at-risk mucosa (211,212). As discussed by Kim (213), folate restriction alone
has the ability to reduce basal proliferation rates in animal tumor models. In addition, Crott et al. (214)
showed that moderate folate restriction to colon cells affected several cancer-related pathways, including
cell cycle checkpoints, cellular adhesion and migration, and Wnt signaling. Thus, our findings are
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consistent with a role for MDD in modifying adenoma risk by influencing basal mucosal homeostasis.
Furthermore, several recent studies have revealed an role for folate metabolism in the regulation of ISCs
and other stem cells (215,216). These long-term alterations to intestinal epithelial homeostasis provide
additional evidence that dietary MDD may induce changes to ISCs within the normal mucosa associated
with tumor protection.
Dietary MDD caused a significant depletion of intestinal cells expressing Dclk1, a putative stem
cell marker that has been the focus of recent interest (217). Giannakis et al. (217) originally proposed
Dclk1 as a marker for intestinal stem cells after finding that Dclk1 expression was enriched in cells isolated
from the progenitor cell compartment of intestinal crypts in C57Bl/6 mice. Nakanishi et al. (197) later
demonstrated via a series of lineage-tracing experiments that Dclk1+ cells can act as the initiating cell for
intestinal tumors in ApcMin/+ mice and proposed that Dclk1 may represent a marker for “tumor stem cells”.
Importantly, these studies also demonstrated that genetic ablation of Dclk1 + cells dramatically reduced
intestinal tumor burden, suggesting that Dclk1+ cells may provide a target for novel CRC therapies
(197,218). Thus, the tumor protection afforded by dietary methyl donor restriction may be based in part
on a selective reduction in Dclk1+ cell populations. Several recent studies by Westphalen et al.
(198) have demonstrated that loss of Apc function within Dclk1+ stem cells is insufficient to drive tumor
formation. Using Dclk1-CreERT x Apcflox/flox mice, they demonstrate that mice remain tumor-free for up to
18 months after Apc inactivation following tamoxifen injections. However, intermittent, short-term
treatment with dextran sodium sulfate (DSS) subsequent to Apc loss leads to the formation of multiple
intestinal tumors with 100% penetrance, indicating the requirement for a concomitant pro-inflammatory
stimulus (198). Furthermore, in lineage tracing experiments using intestinal organoids cultured with
Wnt3a-supplemented media, Westphalen et al. (198) also showed that treatment with either
macrophage-conditioned media or IL-1β caused a 4-fold increase in Dclk1+ cell-derived crypts. In our
previous study (122), we showed that dietary MDD significantly reduces the expression of a number of
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pro-inflammatory cytokines in the intestine, including IL-1β. Thus, it is possible that dietary MDD inhibits
Dclk1-mediated tumor development via several interrelated mechanisms. Under one scenario, by
reducing the levels of a number of pro-inflammatory mediators within the intestinal mucosa, MDD may
eliminate an important stimulus required for activation of mutated Dclk1+ cells. In addition, the MDD diet
may reduce the overall density of Dclk1+ stem cells within the intestinal crypt compartment, thereby
reducing the probability of Apc loss occurring within these tumor initiating stem cells in ApcΔ14/+ mice.
FOCM is fundamental to cellular homeostasis and genomic integrity, and thus dietary MDD is
unlikely to be applied to the general population as a primary prevention strategy. However, the present
study suggests that even a short-term intervention with MDD diet may provide benefit to certain highrisk subpopulations. One group that may benefit is adolescent FAP patients, in which a defined period of
MDD may suppress polyposis, thereby delaying the need for colectomy. Due to the potential risk
associated with the dual-modulatory effect of folic acid on colorectal tumorigenesis (219), future clinical
application of MDD should be combined with careful monitoring by colonoscopy, which is already used
routinely for FAP patients (180). While most of the side effects of MDD are readily reversible upon methyl
donor repletion, a thorough investigation of the potential effects of MDD on normal development and
cardiovascular integrity will need to be undertaken prior to further clinical applications. However, due to
the long-lasting protective effects of even temporary MDD, a strategy analogous to “short-term
intermittent therapy to eliminate premalignancy” (SITEP) (53) may provide clinical benefit while
minimizing unwanted side effects. By administering short pulses of dietary MDD, it may be possible to
induce persistent changes to the intestinal epithelium that provide long-lasting tumor suppression, while
minimizing exposure to nutritional deficiency. In the future, it will be important to evaluate how the timing
of MDD administration can be modulated to provide an optimal balance between tumor protection and
unwanted side effects. In addition, future efforts to identify specific metabolic and cell-signaling pathways
that are affected by dietary MDD may yield novel targets for chemoprevention.
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In summary, this study provides additional evidence that dietary methyl donor restriction may be
a viable strategy for cancer prevention in high-risk individuals. Our previous study demonstrated that a
diet deficient in methyl donors reduced intestinal tumor incidence by greater than 95% in ApcMin/+
mice. The present study extends these promising results to a second Apc-dependent mouse tumor model,
ApcΔ14/+, and show that the tumor protection afforded by dietary methyl donor restriction is both effective
and long-lasting. Tumor protection is accompanied by long-term changes to intestinal crypt morphology
and cell turnover which may result from alterations to the intestinal stem cell pool, as evidenced by the
depletion of Dclk1+ cells from the crypt base. Finally, several detrimental effects associated with methyl
donor restriction (e.g., reduced body weight gain, hepatic steatosis) are shown to be transient and readily
reversible following methyl donor repletion. Taken together, these results indicate that even temporary
dietary methyl donor restriction in severely tumor-prone mice can induce persistent changes to the
intestinal epithelium that provide long-lasting tumor protection in the adult.
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Chapter 4: Metabolite profiling of mice maintained on a methyl donor deficient diet reveals
metabolic changes associated with tumor protection
4.1 Introduction
Investigations into the effects of folate consumption on the risk of CRC have produced conflicting
results. Early epidemiological studies suggested that folate deficiency increases the risk of CRC in the
general population (173–176). However, a more recent meta-analysis of 50,000 individuals enrolled in 13
different folate supplementation trials found no effect on CRC incidence (115). In contrast to studies in
the general population, studies of certain high-risk individuals suggest that elevated folate intake may
actually increase CRC risk (116,117). This finding is consistent with the results of preclinical studies from
our laboratory (122,220) showing that a diet deficient in the methyl donor nutrients folate, choline,
methionine and Vitamin B12 inhibits tumor development in Apc-mutant mouse models of CRC. These
studies suggest that reduced methyl donor intake may benefit individuals at elevated risk of CRC. Our
most recent study (220) demonstrated that even temporary dietary methyl donor deficiency (MDD)
provides long-lasting tumor protection that is associated with persistent changes to the intestinal
epithelium.
At present, the metabolic pathways through which the MDD diet affects changes to the intestinal
epithelium and reduces CRC risk are unknown. Because the methyl donor nutrients depleted from the
MDD diet all play a role in FOCM, this pathway is predicted to be heavily impacted by MDD. FOCM is
responsible for several fundamental biosynthetic processes including the production of nucleotides and
the generation of SAM, the “universal methyl donor”, which is required for the methylation of DNA and
histones (221). FOCM has also been shown to interact with many other metabolic systems, including lipid
and energy metabolism (222). These functions make FOCM critical to cellular homeostasis; disruption of
FOCM can compromise DNA stability, alter gene expression, and inhibit cellular proliferation and survival
(223). Furthermore, methyl donor nutrients contribute to many metabolic functions independent of
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FOCM, including the synthesis of phospho- and sphingolipids, proteins, hormones and other small
molecules (222). While drugs that disrupt FOCM and downstream pathways have been used to
successfully treat CRC for decades (223), there are currently no cancer prevention strategies based on the
manipulation of these pathways.
Our previous studies (122,220) suggest that the manipulation of methyl donor metabolism is a
promising approach to the prevention of CRC. However, the MDD diet was associated with a number of
adverse effects that, while reversible, may limit its clinical efficacy. Investigating the specific metabolic
pathways that are disrupted under conditions of dietary MDD may help to identify novel targets for safer
and more effective CRC prevention strategies. To achieve this goal, the present study uses an untargeted
metabolomic profiling platform to quantify ~400 biochemicals within samples of mouse colonic mucosa
collected in our previous dietary study (220). Using this approach, we have shown that dietary MDD is
associated with extensive metabolic changes, a subset of which persist following methyl donor repletion.
These metabolic changes were enriched in several key pathways, including the methionine cycle, the
transsulfuration pathway, secondary bile acid synthesis, and fatty acid β-oxidation. These observations
provide clues to the molecular changes underlying MDD-induced tumor protection and identify
metabolomic features of the MDD diet that may provide new targets for CRC prevention.

4.2 Materials and Methods
Animal Treatment and Sample Collection
Dietary experiments using ApcΔ14/+ mice and collection of colonic tissue samples have previously
been described in detail (220). Animal experiments were conducted with approval from the Institutional
Animal Care and Use Committee, UConn Health. Briefly, dietary studies used two amino-acid defined
experimental diets: the Methyl Donor Sufficient (MDS; TD.99366, Harlan Laboratories, Madison WI) diet
and the Methyl Donor Deficient (MDD; TD.00605) diet, which was identical to the MDS diet except for the
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depletion of folate, choline, methionine and vitamin B12, and the addition of homocysteine. Full details
of MDS and MDD diet composition have previously been reported (220). Apc14/+ mice were randomized
at 4 weeks of age and placed into four experimental groups; each group was placed on a specific dietary
regimen for 18 weeks as previously reported (220). Briefly, group I (MDS ad libitum, “AL”, n=28) mice were
fed the MDS diet ad libitum for the entire 18-week period. Group II (MDD, n=19) mice were fed the MDD
diet ad libitum for 18 weeks. Group III (MDS-PF, “PF”, n=27) mice were pair-fed the MDS diet in an amount
equivalent to levels consumed by Group II mice. Finally, mice in Group IV (MDD:MDS-Repletion, “R”, n=28)
were placed on the MDD diet for 11 weeks, and then switched to the MDS diet for the remaining 7 weeks.
All mice were sacrificed at 22 weeks of age. Upon sacrifice, colons were harvested, flushed with ice-cold
PBS and opened longitudinally. Normal-appearing mucosa was scraped from the distal 2-3 cm of the colon
and immediately snap-frozen. Mucosa samples were stored at -80C until analysis.

Metabolite Profiling
Fifty mg of snap-frozen, normal-appearing colonic mucosa was shipped to Metabolon, Inc.
(Durham, NC) on dry ice for metabolite quantification. Upon receipt, samples were stored at -80C until
processing. The platform used for sample preparation and analysis has been previously described in detail
(224,225). Briefly, tissue samples were mechanically disrupted and homogenized using a GenoGrinder
2000 (Glen Mills, Inc.) and metabolites were extracted using cold methanol precipitation. Tissue extracts
were split into 3 aliquots: one for analysis by UPLC-MS/MS with positive ion electrospray ionization, one
for analysis by UPLC-MS/MS with negative ion electrospray ionization, and one for analysis by GC-MS. For
LC, the samples were stored overnight under nitrogen before preparation for analysis. For GC, each
sample was dried under vacuum overnight before preparation for analysis. Reproducibility of the
extraction and chromatography procedures was assessed by spiking in xenobiotic compounds at known
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concentrations. GC/LC-MS parameters including column retention time, spectral peaks, and mass-tocharge ratio were compared to a proprietary reference chemical library to identify metabolites.

Bioinformatics and Biostatistics
MS peaks representing metabolites of interest were quantified by calculating the area under the
curve. Missing values were assumed to be below the limit of detection and were imputed with the
minimum observed value for each given compound. When necessary, biochemical data was normalized
to total protein to account for differences in metabolite levels due to differences in the amount of material
present in each sample. For analyses across multiple days, a data normalization step was performed to
correct variation resulting from instrument inter-day variability. Each compound was corrected in run-day
blocks by setting the medians equal to 1 and normalizing each data point proportionately (termed the
“block correction”). Statistical analysis of mean metabolite levels was performed using Welch’s twosample t-test followed by false discovery rate (FDR) correction using the Benjamini-Hochberg procedure.
Differences with an FDR-corrected P-value < 0.05 were considered to be statistically significant. Random
Forest Analysis (RFA), an ensemble machine learning technique, was used to generate metabolite
signatures that allowed accurate classification of de-identified samples into experimental groups. Mean
Decrease Accuracy (MDA) analysis was used to quantify the importance of individual metabolites to
accurate classification by RFA. Hierarchical clustering of samples was done by calculating Euclidean
distance between samples, and dimensionality was reduced using Principal Component Analysis (PCA).
RFA, MDA, clustering and PCA were done using the R programming language and software environment.
Pathway analysis was done by calculating relative-betweenness centrality using MetaboAnalyst 3.0 (226).
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4.3 Results
Dietary methyl donor deficiency is associated with a distinct colonic metabolite profile
Our recent study (220) demonstrated that ApcΔ14/+ mice fed a diet deficient in methyl donor
nutrients benefit from dramatic intestinal tumor protection that persists after mice are returned to a
control diet. To explore the molecular changes associated with MDD that may underlie this protection,
we conducted GC/LC-MS-based metabolite profiling of normal colonic mucosa harvested from mice in our
previous study (220). Using a previously described metabolomics platform (224), 388 unique metabolites
were quantified in 7 mice from each of the 4 experimental groups; these “metabolite profiles” were used
for all subsequent analyses. As shown in Figure 4-1A, MDD samples are separated from MDS ad libitum,
MDS pair-fed, and MDD:MDS-Repletion samples by PCA, indicating that MDD is associated with a distinct
metabolic profile. Furthermore, PCA reveals that metabolite profiles of mice in the MDD:MDS-Repletion
group only partially overlap with those from mice in the MDS ad libitum and MDS pair-fed groups,
suggesting that some metabolic changes persist within the colonic mucosa after a return to the MDS
control diet. The association of MDD with a unique metabolite signature was underscored by RFA, which
was able to accurately distinguish between MDD and MDS-AL mice, as well as between MDD and MDS-PF
mice, with 100% accuracy. By comparing the profiles of MDD and MDS-PF mice, it is possible to identify
metabolic changes due specifically to deficiency in methyl donor nutrients. As shown in Figure 4-1B, the
30 metabolites most important to the accurate separation of MDD and MDS-PF samples by RFA were
identified using MDA analysis. These 30 metabolites were classified into functional subgroups and were
used as a starting point to identify the metabolic pathways most significantly affected by dietary MDD.
Subgroup classifications for these metabolites, as well as their fold-changes in MDD samples relative to
MDS-PF, are shown in Table 4-1. By manually investigating all metabolites within the subgroups identified
in this way, we were able to identify the three metabolic pathways with the greatest number of MDD-
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Figure 4-1. Identification of a metabolite profile associated with dietary MDD. (A) Principal component
analysis (PCA) biplot showing separation of MDD samples from the other experimental groups, indicating
a distinct metabolic profile. Partial overlap of MDD:MDS samples with both MDS ad libitum and MDS pairfed controls suggests that some metabolic changes persist at least 7 weeks beyond methyl donor
repletion. (B) Top 30 metabolites ranked by importance to separation of MDD and MDS-PF samples by
Random Forest Analysis (RFA). These metabolites were used as a stating point in the identification of
metabolic pathways most significantly affected by dietary MDD.

84

Table 4-1. Fold-changes and subgroup classification of Top 30 metabolites identified by RFA.
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associated metabolic changes: Methionine and Cysteine Metabolism, Bile Acid Metabolism, and Carnitinedependent Fatty Acid Oxidation (FAO).

MDD reduces methionine cycle flux and increases transsulfuration pathway flux
We predicted that mice fed the MDD diet would experience reduced levels of methyl donor
nutrients within the colonic mucosa. As shown in Figure 4-2A&B, mice fed the MDD diet showed
significant reductions in the levels of methionine (-2.9-fold, P<0.001) and betaine (-3.3-fold, P<0.001), the
metabolite immediately downstream of choline, relative to MDS ad libitum control mice, validating our
prediction. Furthermore, as shown in Figure 4-2C, MDD mice exhibited a dramatic increase in the level of
homocysteine (109-fold, P<0.001) relative to control, again consistent with our prediction. This substantial
increase in homocysteine was accompanied by an increase in S-adenosylhomocysteine (SAH) (17.1-fold,
P<0.001) (Figure 4-2D), a metabolite normally produced by demethylation of the “universal methyl donor”
S-adenosylmethionine (SAM) (221). As shown in Figure 4-2E-G, MDD was also associated with increases
in cystathionine (11.5-fold, P<0.001), 2-hydroxybutyrate (3.5-fold, P<0.01) and cysteine (4.0-fold, P<0.05),
suggesting increased flux through the cysteine-generating transsulfuration pathway (227). Cysteine
produced via the transsulfuration pathway can be utilized in downstream pathways involved in the
buffering of oxidative stress (227). As shown in Figure 4-2H&I MDD mice exhibited increases in
hypotaurine (2.9-fold, P<0.01) and glutathione disulfide (1.3-fold, P<0.05) suggesting taurine and
glutathione metabolism, two critical antioxidant mechanisms, are upregulated in MDD mice. A depiction
of the methionine and cysteine metabolism changes associated with dietary MDD is shown in Figure 4-3.
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Figure 4-2. Changes in the levels of metabolites involved in the methionine cycle and the
transsulfuration pathway. Levels of methionine (A; -2.9-fold, P<0.001), betaine (B; -3.3-fold, P<0.001),
homocysteine (C; 109-fold, P<0.001), s-adenosylmethionine (D; 17.1-fold, P<0.001), cystathionine (E;
11.5-fold, P<0.001), 2-hydroxybutyrate (F; 3.5-fold, P<0.01), cysteine (G; 4.0-fold, P<0.05), hypotaurine
(H; 2.9-fold, P<0.01), and glutathione disulfide (I; 1.3-fold, P<0.05) are all altered under conditions of
dietary methyl donor restriction. Whiskers on Tukey’s box plots represent Interquartile Range (IQR).
Statistically significant differences (P<0.05) between groups, measured by ANOVA with Bonferroni’s posttest, are indicated within bar graphs by differences in the letter placed above each group.
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Figure 4-3. Schematic overview of metabolic changes to the methionine cycle and transsulfuration
pathway under conditions of dietary MDD. Consistent with the composition of the MDD diet, levels of
methionine and betaine in the colonic mucosa were significantly reduced. Furthermore, levels of
homocysteine were significantly increased, leading to increased flux through the transsulfuration
pathway.
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MDD inhibits production of secondary bile acids (BAs)
Unexpectedly, metabolite profiling revealed reduced levels of secondary bile acids within the
colonic mucosa of MDD mice. Secondary BAs have previously been suggested to promote colorectal
carcinogenesis (228). As shown in Figure 4-4A&B, dietary MDD was associated with decreased levels of
deoxycholate (-4.5-fold, P<0.05) and its taurine-conjugated bile salt taurodeoxycholate (-2.2-fold, P<0.01)
within the colonic mucosa, relative to MDS ad libitum control. Furthermore, as shown in Figure 4-4C-E,
dietary MDD was associated with reductions in levels of α-Muricholate (-3.8-fold, P<0.005), β-Muricholate
(-2.2-fold, P<0.05), and Murideoxycholate (-2.6-fold, P<0.05), the predominant murine secondary bile
acids. Together, these data suggest that dietary MDD inhibits the synthesis of secondary bile acids. A
depiction of the changes to secondary bile acid metabolism is shown in Figure 4-5.

MDD inhibits carnitine-dependent FAO
A large number of metabolites identified by MDA analysis were classified as acylcarnitines.
Acylcarnitines are fatty acid-derived acyl groups conjugated to the shuttle molecule carnitine that are
transported into the mitochondrial matrix to be oxidized for energy production (66). As shown in Figure
4-6A, a panel of acylcarnitines was reduced within the colonic mucosa of MDD mice, including
acetylcarnitine (-1.8-fold, P<0.001), propionylcarnitine (-2.0-fold, P<0.05), hydroxybutyrylcarnitine (-1.7fold, P<0.01), valerylcarnitine (-3.4-fold, P<0.001), hexanoylcarnitine (-3.0-fold, P<0.01), octanoylcarnitine
(-3.0-fold, P<0.05), palmitoylcarnitine (-2.1-fold, P<0.05), and oleoylcarntine (-2.2-fold, P<0.05).
Decreased acylcarnitine levels are likely a consequence of limited availability of carnitine (-2.0-fold,
P<0.01), which is synthesized from methionine (229) and was significantly reduced in the mucosa of MDD
mice relative to MDS ad libitum control (Figure 4-6B). The oxidation of acylcarnitines within the
mitochondrial matrix produces the critical energy metabolism cofactors Acetyl CoA (Figure 4-6C), which
was also reduced in MDD mice (-2.5-fold, P<0.05). Together, these results suggest that dietary MDD
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Figure 4-4. Changes in the levels of metabolites involved in secondary bile acid (BA) synthesis. Levels of
deoxycholate (A; -4.5-fold, P<0.05), taurodeoxycholate (B; -2.2-fold, P<0.01), alpha-muricholate (C; -3.8fold, P<0.005), beta-muricholate (D; -2.2-fold, P<0.05), and murideoxycholate (E; -2.6-fold, P<0.05) are
altered under conditions of dietary methyl donor restriction, suggesting inhibition of secondary BA
synthesis. Whiskers on Tukey’s box plots represent Interquartile Range (IQR). Statistically significant
differences (P<0.05) between groups, measured by ANOVA with Bonferroni’s post-test, are indicated
within bar graphs by differences in the letter placed above each group.
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Figure 4-5. Schematic overview of the metabolic changes to secondary bile acid metabolism under
conditions of dietary MDD. Dietary methyl donor deficiency significantly reduces levels of secondary bile
acids, which are known to promote intestinal tumorigenesis, within the colonic mucosa.
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Figure 4-6. Changes in the levels of metabolites involved in fatty acid β-oxidation (FAO). (A) Levels of a
panel of acylcarnitines, as well as carnitine (B; -2.0-fold, P<0.01) and acetyl CoA (C;-2.5-fold, P<0.05) are
reduced under conditions of dietary methyl donor restriction, suggesting inhibition of FAO. Whiskers on
Tukey’s box plots represent Interquartile Range (IQR). Statistically significant differences (P<0.05)
between groups, measured by ANOVA with Bonferroni’s post-test, are indicated within bar graphs by
differences in the letter placed above each group.
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inhibits mitochondrial FAO, possibly leading to impaired Acetyl CoA-dependent energy metabolism. A
depiction of the changes to carnitine-dependent FAO is shown in Figure 4-7.

MDD causes persistent changes to intestinal redox balance
As previously described (220), dietary MDD confers long-lasting tumor protection to ApcΔ14/+ mice,
which persists for at least 7 weeks beyond active deficiency. To determine whether persistent tumor
protection is associated with persistent metabolic changes, we normalized MDD and MDD:MDS-Repletion
metabolite profiles to MDS ad libitum control and compared the two normalized profiles to identify
metabolite levels that were significantly altered in both groups. Metabolite changes identified in this way
are referred to as “retained changes”. As shown in Figure 4-8A, pathway analysis of retained changes
using MetaboAnalyst 3.0 showed that these changes were enriched in several pathways involved in redox
balance, including Taurine and Hypotaurine Metabolism, and Ascorbate Metabolism. As shown in Figure
4-2H, levels of hypotaurine, which are elevated in MDD mice, are also elevated in MDD:MDS-Repletion
mice (1.3-fold, P<0.05) relative to MDS ad libitum. Similarly, as shown in Figure 4-8B&C, levels of
ascorbate, a potent antioxidant (230), are elevated in both MDD (1.4-fold, P<0.05) and MDD:MDSRepletion mice (1.2-fold, P<0.05), as are levels of UDP-glucuronate (MDD, 1.8-fold, P<0.05; MDD:MDS-R,
1.6-fold, P<0.05), an intermediate in ascorbate synthesis. Together, these results suggest that ascorbate
metabolism is persistently upregulated following temporary MDD. Finally, levels of indoxyl sulfate, a prooxidant toxin produced by intestinal microbes (231), were reduced in both MDD (-2.1-fold, P<0.05) and
MDD:MDS-Repletion mice (-1.3-fold, P<0.05) (Figure 4-8D). Together, these results suggest the that
dietary MDD persistently alters multiple pathways involved in redox balance, possibly leading to reduced
oxidative stress. To further investigate the effects of temporary MDD on oxidative stress, we used the
Thiobarbituric acid reactive substances (TBARS) assay to quantify levels of malondialdehyde (MDA) within
colonic mucosa samples. MDA is a product of lipid peroxidation that is frequently used as a marker for
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Figure 4-7. Schematic overview of the metabolic changes to mitochondrial fatty acid β-oxidation under
conditions of dietary MDD. Levels of carnitine, which is synthesized from methionine, are significantly
reduced within the colonic mucosa under conditions of dietary MDD. As a result, levels of a panel of
acylcarnitines are reduced, inhibiting mitochondrial fatty acid beta oxidation and the production of AcetylCoA.
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Figure 4-8. Identification of MDD-associated metabolic changes that persist during methyl donor
repletion. (A) Biplot of metabolite set enrichment analysis (MSEA) depicting metabolic pathways
significantly enriched for persistent changes. Three pathways involved in redox balance were observed to
be significantly enriched for persistent changes: taurine and hypotaurine metabolism, pentose
metabolism, and ascorbate metabolism. The size and color of each point represents the number of
metabolites within the pathway and the p-value, respectively. Pathway Impact represents the number of
unique metabolic pathways that interact with a given pathway. (B) Levels of ascorbate, a potent
antioxidant, are increased in both MDD (1.4-fold, P<0.05) and MDD:MDS-Repletion mice (1.2-fold,
P<0.05). (C) Levels of UDP-glucoronate, and intermediate in the synthesis of ascorbate are also elevated
in MDD (1.8-fold, P<0.05) and MDD:MDS-Repletion mice (1.2-fold, P<0.05), suggesting persistent
upregulation of ascorbate synthesis following temporary MDD. (D) Levels of indoxyl sulfate, a pro-oxidant
bacterial toxin, are reduced in both MDD (-2.1-fold, P<0.05) and MDD:MDS-Repletion mice (-1.3-fold,
P<0.05). (E) Levels of malondialdehyde (MDA), a marker of oxidative stress measured by the TBARS assay
are significantly reduced in both MDD (-2.5-fold, P<0.05) and MDD:MDS-Repletion mice (-1.7-fold,
P<0.05). Together, these results suggest oxidative stress is persistently reduced within the colonic mucosa
following temporary MDD. Whiskers on Tukey’s box plots represent Interquartile Range (IQR). Error bars
in (E) represent SEM. Statistically significant differences (P<0.05) between groups, measured by ANOVA
with Bonferroni’s post-test, are indicated within bar graphs by differences in the letter placed above each
group.
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Figure 4-8
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oxidative stress (232). As shown in Figure 4-8E, MDA levels are significantly reduced in both MDD (-2.5fold, P<0.05) and MDD:MDS-Repletion mice (-1.7-fold, P<0.05), suggesting that dietary MDD persistently
reduces oxidative stress within the colonic mucosa.

4.4 Discussion
This study expands on our previous work (122,220) by identifying several metabolic pathways that
are altered under conditions of dietary MDD and may contribute to tumor protection. Furthermore, this
study provides clues about the molecular mechanisms underlying the long-lasting nature of MDDassociated tumor protection by identifying a subset of metabolic changes that persist at least 7 weeks
beyond active MDD. The effects of methyl donor nutrient intake on colorectal carcinogenesis are unclear,
with some studies suggesting that high intake of folic acid may be chemoprotective in the general
population (173–176). In contrast, our previous studies (122,220) suggest that reduced intake of methyl
donor nutrients may be a viable strategy for the prevention of CRC in certain high-risk populations.
However, dietary MDD is associated with several unwanted side effects that may complicate the clinical
translation of dietary MDD or limit its utility in the general population. By uncovering metabolic pathways
that are perturbed under conditions of MDD, the present study has uncovered potential biomarkers of
CRC risk and has identified targets for novel preventive interventions. Together, our findings may provide
new avenues for the clinical implementation of chemoprevention strategies based on the manipulation
of FOCM.
As predicted, dietary methyl donor deficiency was associated with extensive changes to FOCM
within the colonic mucosa including reduced availability of methionine and choline and dramatically
increased levels of homocysteine. Several studies have demonstrated that cancer cells have an increased
demand for methionine and are more sensitive to the effects of methionine restriction (MR) than normal
cells (233). As a result of these findings, dietary MR has been proposed as a strategy for CRC prevention.
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As shown by Komninou et al. (234) dietary MR reduced the multiplicity of preneoplastic aberrant crypt
foci (ACF) in F344 rats treated with azoxymethane, supporting this strategy. Our results provide additional
evidence in a genetic model of CRC that MR is a viable strategy for the prevention of CRC, and suggest
that it may be particularly effective in high-risk individuals, such as those with FAP.
MDD was also associated with increased levels of SAH, which is produced directly from
homocysteine by the enzyme SAH hydrolase (235). SAH has previously been shown to inhibit the activity
of DNA methyltransferase enzymes (236,237), and elevated levels of SAH are associated with widespread
DNA hypomethylation (238). As shown by Eads et al. (34) and Weis et al. (35), genetic ablation of DNMT1
and 3a, respectively, prevents the formation of tumors in Apc-mutant mice, indicating a requirement for
de novo DNA methylation in the formation of intestinal polyps. Thus, elevated levels of SAH may
contribute to tumor protection by inhibiting DNMTs and preventing the de novo DNA methylation
associated with polyp formation. Furthermore, since epigenetic modifications to DNA can have long-term
consequences for gene expression (239), it is possible that this metabolic change may contribute to the
long-term tumor protection associated with MDD.
MDD was associated with reduced secondary BA levels within the colonic mucosa. In a seminal
study, Cook et al. (240) demonstrated that prolonged exposure to high BA concentrations induced the
formation of tumors in mice. Since that time, accumulated evidence has illustrated a role for BAs in the
initiation and promotion of CRC (228). Exposure of intestinal epithelial cells to BAs can cause oxidative
stress, DNA damage and apoptosis, with prolonged exposure leading to genomic instability and apoptotic
resistance, two hallmarks of cancer (241). Reducing the level of secondary BAs within the colon may be a
viable strategy for CRC chemoprevention. As shown by Khare et al. (242), treatment of AOM-treated mice
with ursodeoxycholic acid, a synthetic BA that reduces colonic levels of toxic secondary BAs (243),
significantly inhibited tumorigenesis. As reviewed by Payne et al. (241), secondary bile acids damage the
intestinal epithelium, initiate

inflammatory

responses,
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and promote hyperproliferation of

undifferentiated stem and progenitor cells. We have previously reported that dietary MDD is associated
with diminished populations of Dclk1+ stem cells within the intestinal mucosa (220). Dclk1+ cells, which
normally contribute to epithelial repair after mucosal injury (244), are the putative cell-of-origin for
tumors in Apc-mutant mice. Mutant Dclk1+ cells can become activated and initiate tumorigenesis after
exposure to an inflammatory stimulus (198), such as secondary BA exposure. Thus, reduced levels of
secondary BAs within the mucosa may contribute to MDD tumor protection by minimizing oxidative
damage and inflammation, thereby reducing the risk of mutant Dclk1+ cells becoming activated (220).
Together, our results support the use of intestinal BAs as biomarkers for CRC risk and reinforce the
potential for secondary BA synthesis as a chemopreventive target. Furthermore, our studies suggest that
future investigation of the relationship between BA exposure and the activation of tumor-initiating Dclk1+
cells may be warranted.
Metabolite profiling revealed that MDD inhibits FAO by reducing the availability of carnitine,
thereby restricting transport of fatty acids (FAs) into mitochondrial matrices. As reviewed by Carracedo et
al. (66), several recent studies have suggested that cancer cells are dependent on FAO to meet their
increased demands for energy and biosynthetic cofactors, such as Acetyl CoA. There is also growing
evidence that inhibition of FAO is a viable strategy for cancer treatment. As shown by Samudio et al. (245),
treatment of human leukemia cells with etomoxir, an irreversible FAO inhibitor, increases sensitivity to
the induction of apoptosis. Furthermore, as shown by Schlaepfer et al. (68), treatment with etomoxir
significantly inhibits tumor growth in a prostate cancer xenograft model. Thus, our results suggest that
dietary MDD may protect against tumors by inhibiting mitochondrial FAO by impairing the proliferation
and survival of initiated cells within the colonic mucosa. Our results provide additional evidence that FAO
inhibition is a viable strategy for cancer treatment and suggest that a similar approach may be efficacious
in treating CRC. Furthermore, our results extend the scope of possible applications for FAO inhibition by
suggesting that this strategy might also be viable for the prevention of CRC.
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Finally, a set of metabolic changes associated with MDD were also detected in the MDD:MDSRepletion mice, suggesting that they are retained for at least 7 weeks beyond active methyl donor
restriction. These changes predominantly affected pathways involved in managing oxidative stress,
including hypotaurine synthesis, glutathione synthesis, and ascorbate metabolism (246–248). Several
studies have demonstrated that oxidative stress enhances intestinal tumorigenesis in Apc-deficient mice
(249,250). As shown by Cheung et al. (250), genetic deletion of Nrf2, the transcription factor that initiates
glutathione synthesis in response to oxidative stress, leads to increased tumor incidence and multiplicity
in ApcMin/+ mice. The use of individual antioxidants for the prevention of CRC is controversial. A recent
meta-analysis performed by Papaioannou et al. (251) failed to show chemopreventive efficacy for a large
number of single agent interventions, casting doubt on the viability of this approach to cancer prevention.
However, there is some recent evidence that diets which increase total antioxidant capacity (TAC), as
opposed to any single antioxidant, may reduce incidence of CRC (252). The persistent increase in the levels
of multiple antioxidants within the colonic mucosa as a result of MDD suggests that a methyl donor
restricted diet may promote a sustained increase in TAC that reduces the risk of oncogenesis. This
hypothesis is further supported by our observation that markers of oxidative stress are persistently
reduced subsequent to temporary MDD. Together, these results suggest that measurements of TAC may
be useful as a biomarker for CRC risk and suggest that augmenting intestinal TAC may be a viable strategy
for CRC prevention.
In conclusion, this study extends our previous work (122,220) by identifying several metabolic
pathways that are perturbed under conditions of dietary MDD, thereby providing clues to the molecular
changes underlying of MDD-associated tumor protection. As predicted, dietary MDD is associated with
inhibition of the methionine cycle and increased levels of homocysteine within the colonic mucosa, which
led to increased flux through the transsulfuration pathway. Unexpectedly, MDD was also associated with
inhibition of secondary bile acid synthesis and the generation of acetyl CoA via fatty acid β-oxidation.
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Finally, levels of several metabolites involved in redox balance were persistently altered, even after 7
weeks of methyl donor repletion, suggesting tumor protection may be due, in part, to long term
augmentation of colonic antioxidant capacity. Together, these observations identify several metabolic
pathways that may serve as novel targets for CRC detection and chemoprevention.
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Chapter 5: Summary, Conclusions, and Future Directions
CRC incidence and mortality have declined over the last several decades, in large part due to the
increased utilization of screening colonoscopy (2). However, the 5-year survival rate for CRC is 65% overall,
and just 11% for cancers identified in Stage IV (1). Combined with a rapidly aging US population, these low
survival rates underscore the need for improved methods for CRC detection and prevention. FOCM
controls the availability of biosynthetic building blocks and regulates gene expression via DNA methylation
(107,108), making it central to the maintenance of cellular homeostasis. FOCM itself is known to be
disrupted in CRC (128,253), as are many of the processes that it controls, including de novo nucleotide
synthesis, the maintenance of genomic stability, and the regulation of gene expression via DNA
methylation (27,31,254,255). Consistent with these roles in carcinogenesis, FOCM has been used
successfully as a chemotherapeutic target for decades (223). However, less is known about the role of
FOCM in early colonic neoplasia, or its potential as a target for novel CRC prevention strategies.
Intriguingly, FOCM is sensitive to perturbation by environmental influences, especially changes in the
dietary intake of the methyl donor nutrients folate, choline, methionine and vitamin B12 (256–258). Thus,
manipulation of dietary intake of these nutrients represents a promising approach to the modulation of
FOCM. The studies described herein seek to understand the role of FOCM-dependent mechanisms in early
colonic neoplasia and investigate the ability of FOCM manipulation via dietary methyl donor deficiency
(MDD) to disrupt intestinal tumorigenesis. We demonstrate for the first time the extensive disruption of
patterns of DNA methylation, a critical FOCM-dependent mechanism, in the earliest stages of colorectal
neoplasia. Furthermore, these studies demonstrate that manipulation of FOCM via dietary MDD is a viable
strategy for CRC prevention and identify several molecular and cellular targets that may enable the clinical
translation of a FOCM-based prevention strategy.
We report the use of a highly sensitive epigenomic profiling approach that combines LCM with
RRBS and RNA-Seq to identify DNA methylation changes present in KRAS-mutant human ACF and Stage
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III-IV CRCs. Consistent with previous reports of genome-wide methylation loss in a variety of human
cancers (31,155), the majority of DMRs identified in advanced CRCs were globally hypomethylated.
Unexpectedly, the majority of DMRs identified in ACF were hypermethylated, indicating a global gain of
DNA methylation at the earliest stages of colonic tumor initiation. Since the majority of ACF are selflimiting and unlikely to progress to malignancy (93), genome-wide hypermethylation may provide a
mechanism for restricting ACF progression, in part by reducing the risk of genomic instability that is
associated with global loss of methylation (27). Furthermore, the present study uncovered extensive
promoter and gene body hypermethylation of homeobox genes in both cancers and ACF, many of which
belong to the HOX family. The expression of homeobox genes, which is regulated to a large extent by DNA
methylation (164,165), contributes to the maintenance of cellular identity and adult tissue morphology
(166). Aberrant hypermethylation of homeobox-containing genes has been described in breast and lung
cancers, and several HOX genes (HOXA7, HOXA9, and HOXB13) are reportedly hypermethylated in CRC
(158,167,168). However, the large number of differentially methylated homeobox genes identified in our
panel of primary Stage III-IV cancers, and the identification of homeobox gene hypermethylation in ACF,
is an unexpected result that implicates the dysregulation of cellular identity in the earliest stages of colonic
neoplasia.
Promoter DMRs in both CRC and ACF were also enriched in genes known to be targeted by PRC2
in embryonic stem cells (ESCs). PRC2 is a histone-modifying complex expressed in embryonic stem
cells that plays an important role in maintaining ‘stemness' (150) by methylating histone H3K27 and
repressing genes required for differentiation (157). Widschwendter et al. hypothesized that cancerassociated promoter hypermethylation of PRC2 targets originates in stem cells during the earliest stages
of carcinogenesis, and predisposes these cells to neoplastic transformation by “locking in” a stem cell
phenotype (159). Our data support the timing of this hypothesis by demonstrating that hypermethylation
of PRC2 targets occurs as early as the ACF stage.
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Finally, our results indicate that aberrant DNA methylation commonly occurs within intergenic
transcription factor binding sites, especially those corresponding to members of the AP-1 transcription
factor family. Recent evidence indicates that transcriptional activation by AP-1 is controlled, in part, by
DNA methylation (171). As shown by Park et al. (171), the DNA binding activity of AP-1 is significantly
reduced when CpGs in close proximity to its DNA binding motif are methylated. As shown by Berman et
al. (172), intergenic AP-1 binding sequences undergo methylation loss in human CRC. Our data
recapitulate this finding and suggest that loss of methylation at AP-1 sites occurs early in the neoplastic
process.
DNA methylation changes identified within CRC and ACF samples were associated with a variety
of genes and regulatory elements, but the effects of specific epigenetic phenotypes on CRC risk are
currently unknown. In the future, data collected from ACF patients returning for follow-up colonoscopy,
or acquired from The Cancer Genome Atlas (TCGA), could be used to examine the relationship between
particular epigenomic aberrations (e.g. hypermethylation of one or more homeobox genes, AP-1 site
hypomethylation) in precursor lesions and the incidence of advanced neoplasia. Furthermore, while all of
the samples examined in this study harbored KRAS Exon 2 mutations (KRASG12D or KRASG12V), it is unknown
whether KRAS mutations the observed DNA methylation changes. Alternatively, DNA methylation changes
precede the acquisition of somatic mutations and predispose a population of cells to neoplastic
transformation, consistent with the “epigenetic progenitor model” of cancer (259). Recent advances in
intestinal organoid culture technology (260) provide an elegant system for testing the hypothesis that
KRAS mutations directly cause the DNA methylation changes detected in our study. By deriving organoids
from transgenic mice that express Tamoxifen-inducible Cre recombinase and harbor a KRAS Exon 2
mutation downstream of a Lox-Stop-Lox (LSL) cassette, it would be possible to determine the effects of
KRAS mutation acquisition on patterns of DNA methylation. If the induction of a KRAS mutation is found
to cause DNA methylation changes analogous to those identified in human ACF, subsequent study of
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organoid growth characteristics may help shed light on whether these epigenetic changes promote or
prevent the progression of early neoplasia. Furthermore, these studies may serve as a starting point for
chemoprevention studies targeting particular epigenomic features, such as AP-1 binding site
hypomethylation or homeobox gene hypermethylation.
The studies contained herein also demonstrate that manipulation of FOCM via dietary restriction
of the methyl donor nutrients folate, choline, methionine and vitamin B12 is a viable strategy for CRC
prevention. Previously, we demonstrated that a diet deficient in methyl donor nutrients reduced intestinal
tumor incidence by greater than 95% in ApcMin/+ mice (122). The present study extends these promising
results to a second Apc-dependent mouse tumor model, ApcΔ14/+, and shows that the tumor protection
afforded by dietary methyl donor restriction is long-lasting (220). Tumor formation in the ApcΔ14/+ mouse
is driven by an Apc deletion that results in the production of truncated, non-functional APC protein (190).
This mutation is highly homologous to the mutant APC commonly found in FAP patients (261), making the
ApcΔ14/+ mouse a good model of human FAP. Our findings provide additional evidence that dietary MDD
may be a viable strategy for CRC prevention in humans, and suggest that it may have particular efficacy in
individuals with FAP. Furthermore, the observation that temporary MDD imparts persistent protection
suggests that this diet may be amenable to a prevention strategy analogous to “short-term intermittent
therapy to eliminate premalignancy” (SITEP), in which short pulses of an intervention are administered to
clear the colon of premalignant lesions while minimizing unwanted side effects.
MDD tumor protection was associated with altered crypt homeostasis, as evidenced by
alterations to crypt architecture and a reduced frequency of mitotic cells within the crypt epithelium. In a
case-control study by Mills et al. (209), samples of normal mucosa from individuals with either FAP or
sporadic CRC were shown to have an increased frequency of cells in M-phase compared to healthy
controls, indicating a correlation between basal mitotic rate and CRC risk. The most common mechanism
for colonic tumor initiation in Apc-mutant mice is known to be Apc LOH (262), which occurs most
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frequently during mitosis (263). Thus, dietary MDD may protect against tumor initiation by reducing rates
of mitosis, in turn reducing the probability of Apc LOH. Future studies should investigate this mechanism
by measuring the effects of dietary MDD on rates of Apc LOH.
Notably, tumor protection was also associated with reduced rates of crypt fission. Studies by
Fischer et al. (194,206) demonstrated that mutant intestinal crypts in Apc-deficient mice clonally expand
via crypt fission, creating fields of normal-appearing Apc-null crypts that are poised for tumorigenesis. A
follow-up study by the same investigators demonstrated that reduced crypt fission is associated with
decreased tumor multiplicity in Pms2Cre/Cre;ApcCKO/CKO mice (194). Future studies should investigate the
effects of dietary MDD on the occult expansion of Apc-deficient crypts to determine whether inhibition of
this process might underlie tumor protection. Crypt fission is initiated by ISCs in the crypt base (193,195);
thus, further characterization of the effects of dietary MDD on the crypt base ISC compartment may lead
to the identification of cellular targets for novel prevention strategies.
Dietary MDD was also associated with significant depletion of intestinal cells expressing Dclk1, a
putative stem cell marker that has been the focus of recent interest (217). Nakanishi et al. (197)
demonstrated via a series of lineage-tracing experiments that Dclk1+ cells can act as the progenitor for
intestinal tumors in ApcMin/+ mice. Furthermore, these studies showed that genetic ablation of Dclk1+ cells
reduced intestinal tumor burden, suggesting that these cells may provide a target for novel CRC therapies
(197,218). Notably, a recent study by Westphalen et al. (198)

demonstrated that loss

of Apc function within Dclk1+ stem cells is insufficient to drive tumor formation. Using Dclk1-CreERT x
Apcflox/flox mice, the authors demonstrate that mice remain tumor-free for up to 18 months
after Apc inactivation following tamoxifen injections. However, intermittent, short-term treatment with
dextran sodium sulfate (DSS) subsequent to Apc loss leads to the formation of multiple intestinal tumors
with 100% penetrance, indicating a requirement for a concomitant pro-inflammatory stimulus (198). We
have previously shown that dietary MDD is associated with reduced intestinal inflammation (122),
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suggesting a relationship between dietary MDD, reduced inflammation, and the inhibition of Dclk1+ cell
activation. Future studies should investigate the ability of other anti-inflammatory interventions, such as
treatment with NSAIDs, on the frequency and activation of Dclk1+ cells within the intestine.
Finally, these studies show that several adverse effects associated with methyl donor restriction
(e.g., reduced body weight gain, hepatic steatosis, and splenic atrophy) are readily reversible by methyl
donor repletion. Although the reversal of these effects is promising, a thorough characterization of the
adverse effects associated with dietary MDD will need to be completed prior to its clinical translation.
Because dietary MDD may be particularly useful for delaying polyposis in young FAP patients, a thorough
investigation of the effects of MDD on normal development will need to be undertaken prior to clinical
translation. Furthermore, because elevated levels of serum homocysteine, a known consequence of folate
deficiency, increases the risk of cardiovascular disease (264), future studies should also investigate the
effects of dietary MDD on cardiovascular integrity.
Subsequent to our investigation of dietary methyl donor restriction, we used broad-spectrum
metabolite profiling to characterize metabolic changes within the colonic mucosa of mice maintained on
a MDD diet. Using this approach, we identified several pathways that are affected by dietary MDD and
may contribute to tumor protection. As expected, metabolomic analysis revealed extensive changes to
FOCM within the colonic mucosa, including reduced levels of methionine and choline, and dramatically
increased levels of homocysteine. MDD was also associated with increased levels of SAH, which has
previously been shown to inhibit the activity of DNA methyltransferase enzymes (236,237). Consistent
with this effect, Caudill et al. (238) have shown that elevated levels of SAH are associated with widespread
DNA hypomethylation. Epigenetic modifications can have long-term consequences on gene expression
(239), and so it is possible that SAH-mediated DNA methylation changes underlie the persistent alteration
of intestinal homeostasis that is associated with dietary MDD. Future studies should investigate the
relationship between dietary MDD, elevated SAH, DNMT activity, and alterations in DNA methylation.
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Should changes in DNA methylation contribute to the tumor protective effects of dietary MDD, these
results may suggest that SAH itself has potential as a chemopreventive agent in certain populations.
MDD was also associated with dramatically reduced levels of secondary bile acids, which have
been shown by Cook et al. (240) to induce tumorigenesis in mice when administered in high
concentrations. Secondary bile acids are known to initiate inflammatory responses and promote the
proliferation and expansion of undifferentiated ISCs (241). We have previously described diminished
populations of putative tumor-initiating Dclk1+ ISCs under conditions of dietary methyl donor restriction
(220) and hypothesized that the loss of these cells contributes to the tumor-protective effects of the MDD
diet. Future studies should investigate the possibility that secondary bile acids contribute to intestinal
tumor development by promoting the activation and expansion of Dclk1+ cells.
Metabolite profiling also revealed that dietary MDD inhibits mitochondrial FAO by restricting
availability of the shuttle molecule carnitine and inhibiting the synthesis of the metabolic cofactor acetyl
CoA. As reviewed by Carracedo et al. (66), several recent studies have suggested that cancer cells are
dependent on FAO to meet their increased demands for energy, acetyl CoA and other biosynthetic
cofactors. There is also growing evidence that inhibition of FAO is a viable strategy for cancer treatment.
As shown by Samudio et al. (245), treatment of human leukemia cells with etomoxir, an irreversible FAO
inhibitor, increases sensitivity to the induction of apoptosis by genotoxic drugs. Furthermore, as shown
by Schlaepfer et al. (68), treatment with etomoxir significantly inhibits tumor growth in a prostate cancer
xenograft model. Our results extend the scope of possible applications for pharmacologic inhibition of
FAO by suggesting that this strategy may also be efficacious in the prevention and treatment of CRC.
Future studies should examine the ability of existing FAO inhibitors (e.g. etomoxir, perhexiline, and
trimetazidine) to inhibit intestinal oncogenesis or treat existing cancers. Currently, no FAO inhibitors are
approved for human use in the United States. However, successful proof of concept chemoprevention or
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chemotherapeutic studies using the agents listed above may warrant the development of novel FAO
inhibitors with more favorable safety profiles.
Finally, a set of metabolic changes associated with MDD were also detected in the MDD:MDSRepletion mice, suggesting that these changes are retained for at least 7 weeks beyond active methyl
donor restriction. These changes predominantly affected pathways involved in the management of
oxidative stress including hypotaurine synthesis, glutathione synthesis, and ascorbate metabolism (246–
248). Several studies have demonstrated that oxidative stress enhances intestinal tumorigenesis in Apcdeficient mice (249,250). However, the use of individual antioxidants for the prevention of CRC is
controversial. A recent meta-analysis performed by Papaioannou et al. (251) showed that a large number
of single-antioxidant interventions had no effect on colonic tumor incidence. In contrast, there is evidence
to suggest that diets which increase total antioxidant capacity (TAC), as opposed to levels of any single
antioxidant, may reduce incidence of CRC (252). Thus, our findings may warrant further study of the
effects of dietary MDD on intestinal TAC. Furthermore, they suggest that treatment with a combination
of antioxidants in doses sufficient to elevate TAC, rather than a single-agent intervention, may be a viable
strategy for CRC chemoprevention.
In conclusion, the studies described herein advance our understanding of the role of FOCM, and
the homeostatic processes that it controls, in colorectal tumor development. Our human studies have
uncovered a role for aberrant DNA methylation, a gene-regulatory mechanism that is controlled by FOCM,
in the earliest stages of colonic neoplasia. In addition, data from our preclinical dietary intervention
studies provide considerable evidence supporting the use of FOCM inhibition as a strategy for CRC
prevention. Furthermore, by beginning to unravel the molecular mechanisms underlying MDD-associated
tumor protection, we have identified putative molecular and cellular targets for novel chemopreventive
interventions. Together, these findings advance our efforts to develop clinically relevant strategies for the
detection, prevention, and treatment of CRC based on the manipulation of one-carbon metabolism.
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